Roche Diagnostics Operations, Inc.

États‑Unis d’Amérique

Retour au propriétaire

1-100 de 1 483 pour Roche Diagnostics Operations, Inc. Trier par
Recheche Texte
Affiner par
Type PI
        Brevet 1 399
        Marque 84
Juridiction
        États-Unis 1 017
        International 463
        Canada 3
Date
Nouveautés (dernières 4 semaines) 19
2025 juin (MACJ) 16
2025 mai 19
2025 avril 7
2025 mars 5
Voir plus
Classe IPC
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet 289
G01N 35/04 - Détails du transporteur 198
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides 189
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection 114
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques 111
Voir plus
Classe NICE
09 - Appareils et instruments scientifiques et électriques 42
10 - Appareils et instruments médicaux 41
05 - Produits pharmaceutiques, vétérinaires et hygièniques 29
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture 20
42 - Services scientifiques, technologiques et industriels, recherche et conception 6
Voir plus
Statut
En Instance 297
Enregistré / En vigueur 1 186
  1     2     3     ...     15        Prochaine page

1.

A TRANSIMPEDANCE AMPLIFIER CIRCUIT

      
Numéro d'application EP2024088030
Numéro de publication 2025/133212
Statut Délivré - en vigueur
Date de dépôt 2024-12-20
Date de publication 2025-06-26
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Goerzen, Markus
  • Lambertson, Michael

Abrégé

A transimpedance amplifier circuit (110) is proposed, comprising at least one transimpedance amplifier (112). The transimpedance amplifier comprises at least one variable feedback resistor (114) and at least one operational amplifier (116). The variable feedback resistor (114) is connected between an input of an operational amplifier (116) and an output of the operational amplifier (116).

Classes IPC  ?

  • H03F 3/45 - Amplificateurs différentiels
  • H03G 1/00 - Détails des dispositions pour le réglage de l'amplification
  • H03G 3/30 - Commande automatique dans des amplificateurs comportant des dispositifs semi-conducteurs

2.

QUALITATIVE TEST FOR DIRECT ORAL ANTICOAGULANTS (DOACS)

      
Numéro d'application EP2024087250
Numéro de publication 2025/132678
Statut Délivré - en vigueur
Date de dépôt 2024-12-18
Date de publication 2025-06-26
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s) Meyer Dos Santos, Sascha

Abrégé

The present invention concerns the field of point-of-care diagnostics. In particular, it relates to a method for determining an anticoagulant in a blood sample. The method comprises the following steps: a) providing a composition comprising: i) thrombin or a prothrombin activator converting prothrombin into thrombin that is factor Xa (FXa) inhibitor insensitive, or mixtures thereof; and ii) FXa or a prothrombin activator converting prothrombin into thrombin that is FXa inhibitor sensitive, or mixtures thereof; b) contacting a blood sample with the composition thereby generating a mixture of the composition with the blood sample, wherein the mixture comprises at least 0.01 nkat of thrombin activity and at least 0.05 nkat of FXa activity; c) measuring thrombin activity using a substrate capable of detecting thrombin activity; d) comparing the measured thrombin activity to a reference; and e) determining the anticoagulant based on the comparison. Moreover, the invention contemplates a kit for carrying out such methods, working electrodes of an analyte sensor capable of detecting thrombin activity and analyte sensors comprising the same, as well as a devices for determining an anticoagulant in a blood sample.

Classes IPC  ?

  • C12Q 1/56 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des facteurs de coagulation du sang, p. ex. faisant intervenir la thrombine, la thromboplastine, le fibrinogène
  • G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang

3.

MODULAR QUALITY MANAGEMENT SYSTEMS AND METHODS

      
Numéro d'application US2024060073
Numéro de publication 2025/136818
Statut Délivré - en vigueur
Date de dépôt 2024-12-13
Date de publication 2025-06-26
Propriétaire
  • ROCHE MOLECULAR SYSTEMS, INC. (USA)
  • ROCHE SEQUENCING SOLUTIONS, INC. (USA)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
  • ROCHE DIAGNOSTICS INTERNATIONAL AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • VENTANA MEDICAL SYSTEMS, INC. (USA)
Inventeur(s)
  • Arya, Meetu
  • Blair, Timothy Patrick
  • Burek, Devon Margaux
  • Clark, Adam Robert
  • Nebl, Gabriele
  • Nelson, Amy Marie
  • Parris, Kareena
  • Pilz, Matthias

Abrégé

A system for quality control of a medical device or software product including a plurality of quality control (QC) modules, each QC module configured for one or more QC task(s) of a QC process and configured for access by a plurality of users assigned roles and responsibilities for the respective QC task(s), the quality control library configured to store a plurality of QC records including information associated with the QC task(s) and governmental rule(s) or regulation(s) applicable to the respective QC module and medical device product.

Classes IPC  ?

  • G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
  • G06Q 10/0639 - Analyse des performances des employésAnalyse des performances des opérations d’une entreprise ou d’une organisation
  • G06Q 30/018 - Certification d’entreprises ou de produits

4.

TECHNIQUES FOR ILLUMINATION AND DETECTION IN ANALYTICAL ANALYZERS

      
Numéro d'application EP2024086338
Numéro de publication 2025/132105
Statut Délivré - en vigueur
Date de dépôt 2024-12-13
Date de publication 2025-06-26
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s) Wietzorrek, Joachim

Abrégé

In one general aspect, the present disclosure relates to an analytical analyzer (100) including a sample support (107) defining a sample area, an illumination assembly (109) configured to illuminate the sample area with illumination light (9), a matrix detector (6) and a detection assembly (111) configured to image light (7) emitted from the sample area onto the matrix detector (6). The analytical analyzer (100) further includes a field lens array including a plurality of field lens elements (202) arranged over the sample area so that the illumination light (9) and the light (7) emitted from the sample traverses through the field lens array (18) and an opaque grid (103) arranged to cover the edges of each of the plurality of field lens elements (202).

Classes IPC  ?

5.

ANTIBODY AGAINST SKELETAL TROPONIN T AND DIAGNOSTIC USES THEREOF

      
Numéro d'application EP2024087843
Numéro de publication 2025/133083
Statut Délivré - en vigueur
Date de dépôt 2024-12-20
Date de publication 2025-06-26
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Alhusseini, Mohamad Ali
  • Boehm, Kati
  • Gerg, Michael
  • Hillringhaus, Lars
  • Jucknischke, Ute
  • Knoll, Marko
  • Kunzelmann, Stefan
  • Roesser, Alisa
  • Stiegler, Sandrine Carolina

Abrégé

The present invention refers, inter alia, to an antibody against skeletal Troponin T (skTnT), wherein the anti-skTnT antibody is not capable of binding to cardiac Troponin T (cTnT). The present invention also relates to uses of said antibodies for determining a skeletal muscle damage, methods of determining the amount of skTnT, wherein the method comprises contacting a sample with at least one of said antibodies, and determining the amount of skTnT. The invention further refers to corresponding polynucleotides encoding for and compositions comprising said antibody. The invention also relates to a computer-implemented method of determining an amount of skTnT using said antibody.

Classes IPC  ?

  • C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

6.

CARDIAC TROPONIN T QUANTIFICATION

      
Numéro d'application EP2024087793
Numéro de publication 2025/133043
Statut Délivré - en vigueur
Date de dépôt 2024-12-20
Date de publication 2025-06-26
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Alhusseini, Mohamad Ali
  • Boehm, Kati
  • Gerg, Michael
  • Hillringhaus, Lars
  • Jucknischke, Ute
  • Knoll, Marko
  • Kunzelmann, Stefan
  • Roesser, Alisa
  • Stiegler, Sandrine Carolina

Abrégé

The present invention refers, inter alia, to a method of determining the amount of cardiac Troponin T (cTnT) in a sample, said method comprising a) contacting the sample with an anti-cTnT antibody and with an antibody against skeletal Troponin T (anti-skTnT antibody), wherein the anti-cTnT antibody is capable of binding to a cTnT peptide sequence conserved between cTnT and skTnT, wherein the anti-skTnT antibody is not capable of binding to said conserved cTnT peptide sequence, and wherein the anti-skTnT antibody is capable of binding to a skTnT peptide sequence conserved between skTnT and cTnT, thereby preventing binding of the anti-cTnT antibody to skTnT, and b) determining the amount of cTnT; as well as to uses of said antibodies for determining the amount of cTnT, for preventing skTnT interference in determining the amount of cTnT, and/or for maintaining and/or improving specificity and diagnostic accuracy for a disease associated with cTnT.

Classes IPC  ?

  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

7.

METHOD AND SYSTEM FOR APPLYING A LIQUID SAMPLE ONTO A SUBSTRATE FOR IMAGE ANALYSIS

      
Numéro d'application EP2024085313
Numéro de publication 2025/131829
Statut Délivré - en vigueur
Date de dépôt 2024-12-09
Date de publication 2025-06-26
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
  • ROCHE DIAGNOSTICS HEMATOLOGY, INC. (USA)
Inventeur(s)
  • Conroy, Stephen Edward
  • Zahniser, David J
  • Harbers, Rik
  • Karagiannidis, Symeon
  • Kimmig, Anita
  • Poblet Casanovas, Nuria
  • Ruhl, Jaclyn

Abrégé

The present disclosure relates to an automated method for applying a liquid sample (1) onto a substrate (2) for image analysis as well as an automated system (100) for performing the automated method. The automated method comprises providing data corresponding to a property of the liquid sample (1) from a property determination unit (20) to a workflow management unit (90); selecting, by the workflow management unit (90), sample preparation operations based on the property of the liquid sample (1); setting, by the workflow management unit (90), operational parameters based on the selected sample preparation operations and/or on the property of the liquid sample (1); controlling a sample preparation unit (10) to prepare the liquid sample (1) for image analysis by performing the sample preparation operations selected by the workflow management unit (90) and by using the operational parameters set by the workflow management unit (90).

Classes IPC  ?

  • G01N 1/28 - Préparation d'échantillons pour l'analyse
  • G01N 1/30 - TeintureImprégnation
  • G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
  • G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
  • G01N 1/00 - ÉchantillonnagePréparation des éprouvettes pour la recherche
  • G01N 1/31 - Appareils à cet effet
  • G01N 1/38 - Dilution, dispersion ou mélange des échantillons
  • G01N 1/40 - Concentration des échantillons

8.

CALIBRATION MANAGEMENT OF AN IN-VITRO DIAGNOSTIC SYSTEM

      
Numéro d'application 18988760
Statut En instance
Date de dépôt 2024-12-19
Date de la première publication 2025-06-19
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Bruckner, Richard
  • Eicher, Andreas
  • Gan, Li
  • Schwesig-Stelzer, Franz Korbinian

Abrégé

A computer-implemented method of automatically managing calibration of an in-vitro diagnostic (IVD) system comprising executing calibration cycles/procedures comprising using calibration solutions, using a calibration solution comprising a first step of transporting the calibration solution to a measurement unit and a second step of measuring the calibration solution by the measurement unit. For each calibration cycle the method comprises starting repetition of the calibration procedure at the earliest at a start of a buffer time period before expiry of a respective calibration validity period, interrupting the calibration procedure upon receiving an order to execute a sample IVD test and restarting or resuming the calibration procedure after executing the sample IVD test, as long as repetition of the calibration procedure can be restarted or resumed within the buffer time period. Interrupting the calibration procedure comprises different steps depending on whether the order to execute a sample IVD test is received during using a first calibration solution or a subsequent calibration solution in a series of calibration solutions and whether it is received during the first step of transporting the first or a subsequent calibration solution to the measurement unit or the second step of measuring the first or a subsequent calibration solution. An IVD system performing operations associated with the method of automatically managing calibration is also disclosed.

Classes IPC  ?

  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
  • G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection

9.

CHIMERIC IGG-FC-BINDING LIGAND POLYPEPTIDE AND USES THEREOF FOR IGG AFFINITY PURIFICATION

      
Numéro d'application 18433619
Statut En instance
Date de dépôt 2024-02-06
Date de la première publication 2025-06-19
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Eisenhauer, Romina
  • Kroner, Frank
  • Patel, Jigar
  • Schraeml, Michael
  • Strauss, Martin
  • Taeuber, Simone

Abrégé

The present invention relates to a chimeric IgG-Fc-binding ligand polypeptide, comprising a protein fragment of SlyD, wherein the IF domain thereof is replaced by the affinity peptide Fc-III-4C or an Fc-III-XC variant thereof, as well as related uses for IgG affinity purification.

Classes IPC  ?

  • C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
  • C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
  • C12N 1/20 - BactériesLeurs milieux de culture

10.

TRANSDERMAL MEDICAL DEVICE AND KIT COMPRISING THE SAME

      
Numéro d'application EP2024086309
Numéro de publication 2025/125608
Statut Délivré - en vigueur
Date de dépôt 2024-12-13
Date de publication 2025-06-19
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Baer, Ute
  • Gottselig, Alina
  • Grupp, Florian
  • Zahn, Hans

Abrégé

A transdermal medical device (110) is proposed, specifically for sampling of capillary blood, comprising at least one stationary component (118) and at least one movable component (120). The movable component (120) is mounted to the stationary component (118) in a movable manner. The movable component (120) is movable from a distal position (154) to a proximal position (156). The movable component (120) comprises at least one penetration element (140) configured for penetrating the skin of a user. The penetration element (140), in the distal position (154) of the movable component (120), is received within the stationary component (118). In the proximal position (156) of the movable component (120), the penetration element (140) protrudes from an application side (168) of the stationary component (118). The movable component (120) further comprises at least one magnetic driver element (138) which is configured such that a movement of the movable component (120) is drivable by at least one external magnetic force. Further, a body mount (112) for attaching the transdermal medical device (110) to a body surface of a user, a transdermal medical kit (114) comprising the transdermal medical device (110) and the body mount (112), and a method of driving a penetration element (140) are proposed.

Classes IPC  ?

  • A61B 5/15 - Dispositifs de prélèvement d'échantillons de sang
  • A61B 5/151 - Dispositifs de prélèvement d'échantillons de sang spécialement adaptés pour le prélèvement d'échantillons de sang capillaire, p. ex. par des lancettes
  • A61M 5/158 - Aiguilles

11.

HEMOGLOBIN DETERMINATION METHODS AND SYSTEMS

      
Numéro d'application EP2024084508
Numéro de publication 2025/119902
Statut Délivré - en vigueur
Date de dépôt 2024-12-03
Date de publication 2025-06-12
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s) Rieder, Roman

Abrégé

The present invention relates to a method for determining hemoglobin in a sample comprising red blood cells, said method comprising (a) dispensing a first aliquot of said sample on a first working area of a substrate; (b) providing a hemolyzed second aliquot of said sample and dispensing said second aliquot on a second working area; and (c) determining the hemoglobin in said first and second working area, wherein said method comprises a further step of contacting said first working area, but not the second working area, with a treatment solution. The present invention also relates to systems and diagnostic methods related to said method.

Classes IPC  ?

  • G01N 33/72 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les pigments du sang, p. ex. l'hémoglobine, la bilirubine
  • G01N 1/30 - TeintureImprégnation
  • G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang

12.

METHOD AND DEVICES FOR DETECTING A FIBRINOGEN LEVEL IN A SAMPLE

      
Numéro d'application EP2024084819
Numéro de publication 2025/120038
Statut Délivré - en vigueur
Date de dépôt 2024-12-05
Date de publication 2025-06-12
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Bauer-Espindola, Klaus Andreas
  • Lambertson, Michael
  • Meyer Dos Santos, Sascha
  • Schumacher, Dagmar

Abrégé

A test element (110) for detecting a fibrinogen level in a sample (112) of a bodily fluid is disclosed. The test element (110) comprises at least one substrate (114) and at least one capillary (116) for receiving and transporting the sample (112). The test element (110) further comprises at least one test region (118) and at least one control region (120) within the capillary (116), wherein the test element (110), in the test region (118), comprises at least two test electrodes (122), wherein the test element (110), in the control region (120), comprises at least two control electrodes (124). The test element (110) further comprises, in the test region (118), at least one detector compound (126), the detector compound (126) being capable of specifically cleaving fibrinogen.

Classes IPC  ?

  • G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
  • C12Q 1/56 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des facteurs de coagulation du sang, p. ex. faisant intervenir la thrombine, la thromboplastine, le fibrinogène
  • G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang

13.

MEANS AND METHODS FOR DETERMINING FIBRINOGEN USING AN ASSAY BASED ON A COMPETITIVE MECHANISM

      
Numéro d'application EP2024084115
Numéro de publication 2025/114544
Statut Délivré - en vigueur
Date de dépôt 2024-11-29
Date de publication 2025-06-05
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Horn, Carina
  • Meyer Dos Santos, Sascha
  • Schumacher, Dagmar

Abrégé

The present invention concerns the field of point-of-care diagnostics. In particular, it relates to a method for determining fibrinogen in a sample comprising the steps of (a) contacting a fibrinogen binding agent, said fibrinogen binding agent comprising a first molecule which is capable of specifically binding fibrinogen and, reversibly bound to the said first molecule, a second molecule which is capable of specifically binding the first molecule, wherein the affinity of said second molecule for the first molecule is lower than the affinity of fibrinogen for said first molecule, with a sample suspected to comprise fibrinogen for a time and under conditions which allow for specific binding of fibrinogen to said first molecule, whereby the second molecule is released from said first molecule and fibrinogen is specifically bound by the first molecule, (b) determining said second molecule released from said first molecule, and (c) determining fibrinogen in the sample based on the released second molecule. The invention further contemplates a method for assessing coagulation defects or disorders in a subject as well as devices and kits for carrying out such methods.

Classes IPC  ?

  • G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang

14.

SAFE POINT PATTERN

      
Numéro d'application 19004068
Statut En instance
Date de dépôt 2024-12-27
Date de la première publication 2025-06-05
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Oosterbroek, Edwin
  • Schnarwiler, Dominik
  • Sillitoe, Nicolas Seungoon

Abrégé

A method of operating a distribution system having carriers that carry objects and a transport plane supporting the carriers. A grid of logical positions is defined on the transport plane and a drive system moves the carriers between the logical positions. A router calculates routes for the carriers and applies a global pattern of safe points on the transport plane. Safe points are logical positions selected based on a range of motion for a carrier occupying the logical position, such that on the safe points a carrier can be placed and then moved away. The global pattern is applied onto the transport plane independently of module boundaries. Partial routes for the carriers are calculated so that an end position of each partial route is either a safe point or has a free path to a safe point to be reachable in the next partial route using the router.

Classes IPC  ?

  • G05D 1/692 - Commande coordonnée de la position ou du cap de plusieurs véhicules impliquant une pluralité de véhicules disparates
  • G05D 1/644 - Optimisation des paramètres de parcours, p. ex. consommation d’énergie, réduction du temps de parcours ou de la distance
  • G05D 101/00 - Détails des architectures logicielles ou matérielles utilisées pour la commande de la position
  • G05D 105/28 - Applications spécifiques des véhicules commandés pour le transport de marchandises
  • G06Q 10/0835 - Relations entre l’expéditeur ou le fournisseur et les transporteurs

15.

DISTRIBUTION SYSTEM AND METHOD FOR DISTRIBUTING A PLURALITY OF CARRIERS

      
Numéro d'application 19004137
Statut En instance
Date de dépôt 2024-12-27
Date de la première publication 2025-06-05
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Oosterbroek, Edwin
  • Sillitoe, Nicolas Seungoon

Abrégé

A distribution system for distributing carriers has a transport plane with logical positions. The carriers transport objects and a drive system moves the carriers on the transport plane between the logical positions. A controller moves the carriers on a planned route from a start position to a final destination on the transport plane. The planned route is made up of partial routes, and a routing system calculates routing plans for carriers on the transport plane by modeling the transport plane with graphs of nodes. The routing plans are calculated considering moving time periods and waiting time periods. The waiting time periods are assigned based on a reservation of logical positions of the partial routes of other carriers. Thus, if a carrier experiences a time delay during execution of a move, the routing system shifts the experienced time delay to an upcoming waiting time period of a carrier.

Classes IPC  ?

  • G06Q 10/0835 - Relations entre l’expéditeur ou le fournisseur et les transporteurs
  • G05D 1/644 - Optimisation des paramètres de parcours, p. ex. consommation d’énergie, réduction du temps de parcours ou de la distance
  • G05D 1/698 - Attribution des commandes
  • G05D 101/00 - Détails des architectures logicielles ou matérielles utilisées pour la commande de la position
  • G05D 105/28 - Applications spécifiques des véhicules commandés pour le transport de marchandises

16.

MUTANT REVERSE TRANSCRIPTASE WITH INCREASED THERMAL STABILITY AS WELL AS PRODUCTS, METHODS AND USES INVOLVING THE SAME

      
Numéro d'application 19046511
Statut En instance
Date de dépôt 2025-02-05
Date de la première publication 2025-06-05
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Bell, Christian Helmut
  • Sobek, Harald
  • Walch, Heiko
  • Yasukawa, Kiyoshi
  • Baba, Misato

Abrégé

The present invention relates to a mutant reverse transcriptase (RT) with increased thermal stability relative to the wildtype, a nucleic acid encoding the mutant RT, a cell comprising the mutant RT or the nucleic acid, a kit comprising the mutant RT, the use of the mutant RT for cDNA synthesis, method for reverse transcription of RNA comprising synthesizing cDNA with the use of the mutant RT and a method for detecting an RNA marker in a sample with the use of the mutant RT.

Classes IPC  ?

  • C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
  • C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
  • C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

17.

DETECTION ZONE OF A LATERAL FLOW IMMUNOASSAY DEVICE COMPRISING A POLYION MULTILAYER

      
Numéro d'application EP2024082830
Numéro de publication 2025/108930
Statut Délivré - en vigueur
Date de dépôt 2024-11-19
Date de publication 2025-05-30
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Baeumner, Antje
  • Horn, Carina
  • Strohmaier-Nguyen, Dan

Abrégé

A first aspect of the invention is directed to a detection zone of a lateral flow immunoassay device comprising a polyion multilayer, the polyion multilayer comprising (i) at least one layer comprising a complex of at least a first polyion and a first member of a binding pair; and (ii) at least one layer comprising a second polyion, which is oppositely charged with respect to the first polyion. In a second aspect, the invention relates to a lateral flow immunoassay device comprising a capillary channel, wherein the capillary channel houses (I) a detection zone as defined in the first aspect; (II) a first reagent zone, which comprises a labeled binding moiety; and (III) a second reagent zone, which comprises a binding moiety carrying a second member of a binding pair; wherein the binding moieties of (II) and of (III) are both capable of binding an analyte of interest, and the second member of a binding pair is capable of binding with the first member of a binding pair of the detection zone; wherein preferably first reagent zone of (II) and second reagent zone of (III) are spatially separated or overlap with each other at least partially. A third aspect of the invention is directed to the use of the lateral flow immunoassay device of the second aspect for determining an analyte in a sample. In a fourth aspect, the invention is related to a method for determining an analyte in a sample, the method comprising (a) contacting a sample with at least a labeled binding moiety and a binding moiety carrying a second member of a binding pair, thereby forming a mixture; (b) contacting the mixture formed in (a) with a polyion multilayer, the polyion multilayer comprising (i) at least one layer comprising a complex of at least a first polyion and a first member of a binding pair, (ii) at least one layer comprising a second polyion, thereby optionally forming complexes; (c) determining the amount of label containing complexes formed in (b); and (d) determining said analyte in a sample based on the result of step (c). A fifth aspect of the invention relates to a kit for determining an analyte in a sample, comprising the lateral flow immunoassay device of the second aspect and a pump, which is connected or connectable to the suction device.

Classes IPC  ?

  • G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

18.

A MULTI-SIGNAL METHOD FOR CALIBRATING AT LEAST ONE ANALYTE SENSOR FOR DETECTING AT LEAST ONE ANALYTE IN A SAMPLE

      
Numéro d'application EP2024083076
Numéro de publication 2025/109050
Statut Délivré - en vigueur
Date de dépôt 2024-11-21
Date de publication 2025-05-30
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Dagdelen, Oezguer
  • Doerr, Christopher
  • Leichsenring, Ingrid
  • Stickel, Manfred
  • Weisser, Steffen

Abrégé

A method for calibrating at least one analyte sensor for detecting at least one analyte in a sample is proposed. The analyte sensor comprises at least one measurement unit configured for generating at least two at least partially independent sensor signals. Each of the independent sensor signals is dependent on a concentration of the analyte. The method comprises the following steps: a) (110) measuring at least two at least partially independent sensor signals (112, 114) by using the measurement unit on at least one reference sample having a known analyte concentration; b) (116) determining a multidimensional calibration trajectory (118) by combining the measured at least two at least partially independent sensor signals (112, 114) by using at least one processing unit.

Classes IPC  ?

  • G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p. ex. pour planifier la maintenance ou les mises à jour
  • A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

19.

METHOD OF COATING A GLASS FIBER FLEECE, COATED GLASS FIBER FILTER AND USES THEREOF

      
Numéro d'application EP2024083324
Numéro de publication 2025/109187
Statut Délivré - en vigueur
Date de dépôt 2024-11-22
Date de publication 2025-05-30
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Brandstetter, Thomas
  • Frey, Holger
  • Geid, Nicolas
  • Lopez-Calle, Eloisa
  • Marcinowski, Moritz
  • Ruehe, Juergen
  • Scherag, Frank Daniel
  • Spinke, Juergen

Abrégé

The present invention relates to a method for coating a glass fiber fleece comprising contacting the surface of a glass fiber fleece with a hydrophilic copolymer; and crosslinking the copolymer. The invention further relates to a glass fiber filter, comprising a glass fiber fleece, wherein the surface of the glass fiber fleece is coated with a hydrophilic copolymer; and to a device for biomedical filter applications comprising the same.

Classes IPC  ?

  • B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
  • B01D 39/20 - Autres substances filtrantes autoportantes en substance inorganique, p. ex. papier d'amiante ou substance filtrante métallique faite de fils métalliques non-tissés
  • B01D 69/10 - Membranes sur supportSupports pour membranes
  • B01D 71/40 - Polymères d'acides non saturés ou de leurs dérivés, p. ex. sels, amides, imides, nitriles, anhydrides, esters
  • B01D 71/76 - Matériaux macromoléculaires non prévus spécifiquement dans un seul des groupes
  • G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
  • G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur

20.

IVD ANALYZER, IVD CONSUMABLE DEVICE, AND METHOD OF USING THE SAME UNDER SUSCEPTIBILITY TO ENVIRONMENTAL CONDITIONS

      
Numéro d'application EP2024081941
Numéro de publication 2025/103973
Statut Délivré - en vigueur
Date de dépôt 2024-11-12
Date de publication 2025-05-22
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Hoertz, Christian
  • Diechtierow, Michael

Abrégé

A kit comprising an in-vitro diagnostic (IVD) consumable device in an environmentally sealed package, where after opening of the package usability of the IVD consumable device by an IVD analyzer is time-limited within an out-of-package usability time period. The package comprises a package mark, the reading of which triggers the start of the out-of-package usability time period, and the IVD consumable device comprises a consumable-device mark, linked to the package mark, the reading of which determines a time lapse since reading of the package mark and whether the time lapse is within or outside of the out-of-package usability time period. A respective IVD analyzer and a respective method of using the kit together with the IVD analyzer, are herein also disclosed.

Classes IPC  ?

  • B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
  • G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient

21.

IVD SYSTEM AND METHOD OF USING AN IVD CONSUMABLE DEVICE SUSCEPTIBLE TO ENVIRONMENTAL CONDITIONS

      
Numéro d'application EP2024081927
Numéro de publication 2025/103968
Statut Délivré - en vigueur
Date de dépôt 2024-11-12
Date de publication 2025-05-22
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Hoertz, Christian
  • Juergens, Ludger Herbert Joachim

Abrégé

An IVD system comprising an IVD analyzer and an IVD consumable device configured to be used together with the IVD analyzer in order to carry out an IVD test that enables to obtain reliable test results by more reliably determining whether the IVD consumable device is within or outside of an out-of-package usability time period. In particular, the IVD analyzer comprises an optical detector for determining an optically detectable property of at least one indicator, at least one environmental sensor configured to determine a value of at least one environmental parameter affecting change of the optically detectable property over time and a controller configured to correlate the optically detected property of the at least one indicator to the determined value of the at least one environmental parameter by reference to a stored indicator-specific calibration of the optically detectable property obtained under varying values of the at least one environmental parameter.

Classes IPC  ?

  • G01N 31/22 - Utilisation des réactifs chimiques
  • G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
  • G01N 21/84 - Systèmes spécialement adaptés à des applications particulières
  • G04F 13/00 - Appareils pour mesurer des intervalles de temps inconnus par des moyens non prévus dans les groupes

22.

TRANSGLUTAMINASE SUBSTRATES FOR LABELING

      
Numéro d'application 18506002
Statut En instance
Date de dépôt 2023-11-09
Date de la première publication 2025-05-15
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Jochum, Simon
  • Hemann, Matthias
  • Benz, Juliane

Abrégé

Fusion polypeptides are disclosed which are substrates for Kutzneria albida transglutaminase. The fusion polypeptides comprise one or more FKBP chaperone(s) and a target polypeptide. Each of these elements is separated from the neighboring element by a linker amino acid sequence. It was found that inserting glutamic acid containing transglutaminase recognition motifs into the linker amino acid chains is advantageous. Subsequent labeling reactions catalyzed by the transglutaminase surprisingly provide labeled fusion polypeptides have superior properties when compared with chemically random-labeled fusion polypeptides of similar design. Assays and kits are provided for in vitro detection of target antibodies in samples.

Classes IPC  ?

  • G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
  • C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
  • C12N 9/10 - Transférases (2.)
  • G01N 33/532 - Production de composés immunochimiques marqués

23.

HIGH AFFINITY ANTIBODIES SPECIFICALLY BINDING TO a-1,6-CORE-FUCOSYLATED ALPHA-FETOPROTEIN

      
Numéro d'application 18951180
Statut En instance
Date de dépôt 2024-11-18
Date de la première publication 2025-05-15
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Gerg, Michael
  • Hillringhaus, Lars
  • Jucknischke, Ute
  • Muth, Anna Christine
  • Oelschlaegel, Tobias
  • Pinchuk, Boris
  • Schraeml, Michael
  • Siebenhaar, Joanna
  • Thirault, Laurence

Abrégé

The present invention relates to monoclonal antibodies and antigen binding fragments that specifically bind to α-1,6-core-fucosylated alpha-fetoprotein (AFP), which is the core component of AFP-L3. Thus, the antibodies and antigen binding fragments provided herein may also be referred to as AFP-L3 antibodies. Also provided are polynucleotides encoding the antibodies or antigen binding fragments of the invention, host cells expressing the antibodies and antigen binding fragments of the invention, methods for producing the antibodies and antigen binding fragments of the invention, and uses of the antibodies and antigen binding fragments of the invention. Also provided herein is a pretreatment agent facilitating the binding of the antibodies and antigen binding fragments of the invention to α-1,6-core-fucosylated AFP. The present invention further relates to kits comprising the antibodies and antigen binding fragments of the invention and optionally the pretreatment agent of the invention.

Classes IPC  ?

  • G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
  • C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

24.

Parts Anomaly Detection System, Automatic Analyzer and Parts Anomaly Detection Method

      
Numéro d'application 18834169
Statut En instance
Date de dépôt 2022-12-14
Date de la première publication 2025-05-15
Propriétaire
  • Hitachi High-Tech Corporation (Japon)
  • Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Sasaki, Shunsuke
  • Imai, Kenta
  • Hadorn, Maik Roger
  • Kuehnl, Michael
  • Pukas, Darius
  • Brzezinski, Mikolaj
  • Marchewa, Janusz

Abrégé

Such a parts anomaly detection system is provided as being able to detect the anomaly of the parts of the liquid transport system of the automatic analyzer without delay. Such a parts anomaly detection system is provided as being able to detect the anomaly of the parts of the liquid transport system of the automatic analyzer without delay. The parts anomaly detection system to detect the anomaly of the parts of the liquid transport system (22) which absorbs and discharges liquid with respect to a sensor (21) for sample inspection of an automatic analyzer (1) comprises: storage devices (31, 41) to store data of electric signals outputted by the sensor and processing devices (32, 42) to process the data recorded in the storage devices, in which the processing devices detect the anomaly of the parts of the liquid transport system based on the electric signals.

Classes IPC  ?

  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet

25.

INSERT, CENTRIFUGE, AND ANALYTICAL INSTRUMENT

      
Numéro d'application 18944098
Statut En instance
Date de dépôt 2024-11-12
Date de la première publication 2025-05-15
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Bauer, Andreas
  • Hess, Peter
  • Stein, Reiner
  • Thome, Klaus
  • Gruen, Markus
  • Gruber, Benjamin
  • Elengical, John

Abrégé

The invention relates to an insert being adapted to be removably inserted into a ring segment shaped gap of a centrifuge, wherein the ring segment shaped gap is formed between a rotor member and a stator member of the centrifuge, wherein the insert is adapted to collect fluids centrifugally ejected from the rotor member.

Classes IPC  ?

  • B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
  • G01N 1/40 - Concentration des échantillons

26.

CALIBRATION TARGET, ANALYTICAL DEVICE, METHOD, AND USE

      
Numéro d'application EP2024081145
Numéro de publication 2025/098972
Statut Délivré - en vigueur
Date de dépôt 2024-11-05
Date de publication 2025-05-15
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s) Hebestreit, Kai

Abrégé

The invention relates to a calibration target (1) for calibrating an analytical device (20), wherein the calibration target (1) comprises an electrophoretic display (2) comprising first particles (P1) and second particles (P2), wherein the first particles (P1) and the second particles (P2) differ in at least one property, wherein the electrophoretic display (2) is controllable for displaying a calibration image (I) using the first particles (P1) and/or the second particles (P2).

Classes IPC  ?

  • G02F 1/167 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur le mouvement de translation des particules dans un fluide sous l’influence de l’application d’un champ caractérisés par l’effet électro-optique ou magnéto-optique par électrophorèse
  • G01N 21/27 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
  • G02F 1/1675 - Détails de construction

27.

Method of operating a laboratory sample distribution system, laboratory sample distribution system, and laboratory automation system

      
Numéro d'application 19017141
Statut En instance
Date de dépôt 2025-01-10
Date de la première publication 2025-05-08
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Janner, Gabriele Piero
  • Ng, Cho Yiu
  • Ren, Shubin

Abrégé

The disclosure refers to a method of operating a laboratory sample distribution system having: a plurality of carriers (4) having a number of n (n>3) carriers (4) each configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) configured to support to the plurality of carriers (4), wherein the transport plane (1) comprises a plurality of interconnected transport modules comprising a plurality of plane fields (5); and a driving device (13) configured to control movement of the plurality of carriers (4) along individual routes between the plurality of plane fields (5). The method comprises: moving the plurality of carriers (4) along the individual routes on the transport plane (1), wherein the moving, for each carrier, comprises executing at least once steps of reserving a route segment along the individual route, the route segment being provided by one or more plane fields of the plurality of plane fields (5), and moving the carrier (4) along the route segment; and preventing, for the plurality of carriers (4), a deadlock arrangement on the transport plane in which the plurality of carriers (4) block each other from further movement along the individual routes (6). The preventing is further comprising: determining, at a present operation time, a potential deadlock arrangement for the plurality of carriers (4) on the transport plane (1) at a future operation time, wherein the potential deadlock arrangement is assigned a number of n deadlock plane fields occupied by the plurality of carriers (4) in case of the potential deadlock arrangement; for a first carrier from the plurality of carriers (4) moving along a first individual route, reserving a first route segment ending with a first end plane field; and assigning a non-reserve flag to a next plane field which is next to the first end plane field along the first individual route. Further, a laboratory sample distribution system, and a laboratory automation system are provided.

Classes IPC  ?

  • G01N 35/04 - Détails du transporteur
  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet

28.

TRANSGLUTAMINASE SUBSTRATES FOR LABELING

      
Numéro d'application 18505075
Statut En instance
Date de dépôt 2023-11-08
Date de la première publication 2025-05-08
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Jochum, Simon
  • Hemann, Matthias
  • Benz, Juliane

Abrégé

Fusion polypeptides are disclosed which are substrates for Kutzneria albida transglutaminase. The fusion polypeptides comprise one or more FKBP chaperone(s) and a target polypeptide. Each of these elements is separated from the neighboring element by a linker amino acid sequence. It was found that inserting glutamic acid containing transglutaminase recognition motifs into the linker amino acid chains is advantageous. Subsequent labeling reactions catalyzed by the transglutaminase surprisingly provide labeled fusion polypeptides have superior properties when compared with chemically random-labeled fusion polypeptides of similar design. Assays and kits are provided for in vitro detection of target antibodies in samples.

Classes IPC  ?

  • G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
  • C12N 9/10 - Transférases (2.)
  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

29.

GLYCAN STRUCTURES OF HAPTOGLOBIN AS A BIOMARKER OF HEPATOCELLULAR CARCINOMA

      
Numéro d'application 18931012
Statut En instance
Date de dépôt 2024-10-29
Date de la première publication 2025-05-08
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Busskamp, Holger
  • Kohansal Nodehi, Mahdokht
  • Kroeniger, Konstantin
  • Rolny, Vinzent
  • Swiatek-De Lange, Magdalena
  • Tabares, Gloria

Abrégé

The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject comprising determining the amount of one or more glycan structure at position N207 of haptoglobin (i.e. of the ß-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject. Also disclosed are a glycan structure as well as a glycopeptide comprising said glycan structure, both of great utility in the detection of HCC. Further, the present invention relates to the use of one or more glycan structure at position N207 or of a glycopeptide comprising N207 of haptoglobin in combination with AFP and/or PIVKA in the detection of HCC.

Classes IPC  ?

  • G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
  • C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
  • C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
  • G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

30.

REMOTE ANALYZER MONITORING

      
Numéro d'application 18936946
Statut En instance
Date de dépôt 2024-11-04
Date de la première publication 2025-05-08
Propriétaire
  • Roche Diagnostics International AG (Suisse)
  • Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Alexander, Jeffrey
  • Hoogendoorn, Geertje Engelina Adriana Maria
  • Lin, Yi-Chun
  • Winiarz, Jakub

Abrégé

A computer implemented method (60) for remote analyzer monitoring, comprising: obtaining (62), via a computing device (20) comprising a camera (21), visual representation data (70) of at least a display interface (P1-D) of an automated analyzer (P1) after the automated analyzer (P1) has performed a predefined operation, wherein the visual representation data (70) of the display interface (P1-D) comprises data associated with an outcome of the predefined operation performed by the automated analyzer (P1); processing (64) the visual representation data to extract data (74) relating to an outcome of the predefined operation computed by the automated analyzer (P1) and comprised in the visual representation data (70) associated with the predefined operation; evaluating (66) the data associated with the predefined operation according to at least one evaluation criterion to thus generate evaluation data (76); and storing (68) the evaluation data associated with the predefined operation.

Classes IPC  ?

  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet

31.

METHOD FOR CONFIGURATION MANAGEMENT OF AT LEAST ONE LABORATORY ANALYZER SYSTEM

      
Numéro d'application EP2024080556
Numéro de publication 2025/093539
Statut Délivré - en vigueur
Date de dépôt 2024-10-29
Date de publication 2025-05-08
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Roetzer, Marian David
  • Schweinberger, Florian Frank

Abrégé

A computer-implemented method for configuration management of at least one laboratory analyzer system (114) comprising at least one analytical unit (116) is proposed. The method comprises the following steps: a) retrieving at least one item of information on an analytical unit configuration of at least one analytical unit (116) of the laboratory analyzer system (114); b) applying at least one cryptographic function to the item of information on an analytical unit configuration thereby generating a secured item of information on an analytical unit configuration; c) providing the secured item of information on an analytical unit configuration to at least one database (122) of the laboratory analyzer system (114) and/or to at least one remote central database (118), wherein the remote central database (118) is at the manufacturer's site and/or a cloud database.

Classes IPC  ?

  • G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p. ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
  • G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p. ex. pour planifier la maintenance ou les mises à jour
  • H04L 9/32 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système

32.

COBAS ULTIMATE

      
Numéro de série 99165410
Statut En instance
Date de dépôt 2025-05-01
Propriétaire Roche Diagnostics Operations, Inc. ()
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 10 - Appareils et instruments médicaux

Produits et services

Laboratory instrument for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for use in research, science and industry; computer hardware and software for use with laboratory instruments, namely, for use in providing automation of laboratory processes, control and monitoring of laboratory instruments, connectivity, data analysis, and data management Medical apparatus for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for medical diagnostic purposes

33.

COBAS SMART

      
Numéro de série 99165444
Statut En instance
Date de dépôt 2025-05-01
Propriétaire Roche Diagnostics Operations, Inc. ()
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 10 - Appareils et instruments médicaux

Produits et services

Laboratory instrument for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for use in research, science and industry; computer hardware and downloadable software for use with laboratory instruments, namely, for use in providing automation of laboratory processes, control and monitoring of laboratory instruments, connectivity, data analysis, and data management Medical apparatus for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for medical diagnostic purposes

34.

GLYCAN STRUCTURES OF HAPTOGLOBIN AS A BIOMARKER OF HEPATOCELLULAR CARCINOMA

      
Numéro d'application 18930774
Statut En instance
Date de dépôt 2024-10-29
Date de la première publication 2025-05-01
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Rolny, Vinzent
  • Busskamp, Holger
  • Kroeniger, Konstantin
  • Kohansal Nodehi, Mahdokht
  • Swiatek-De Lange, Magdalena
  • Tabares, Gloria

Abrégé

The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject. The method may comprise determining the amount of one or more N-glycan structure attached to haptoglobin (i.e. of the β-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject and comparing the amount of said one or more glycan structure to a reference amount of said one or more glycan structure, wherein an altered amount of said one or more glycan structure in said patient sample relative to the reference amount of said one or more glycan structure is indicative for HCC. Further, the present invention relates to the use of one or more glycan structure attached to haptoglobinor of a glycopeptide derived from haptoglobin in combination with AFP and/or PIVKA-II in the detection of HCC.

Classes IPC  ?

  • G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

35.

COMPOUNDS FOR STABILIZING PEPTIDES IN BIOLOGICAL SAMPLES

      
Numéro d'application EP2024079880
Numéro de publication 2025/087937
Statut Délivré - en vigueur
Date de dépôt 2024-10-23
Date de publication 2025-05-01
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Pirkl, Nicole
  • Rempt, Martin

Abrégé

The present invention provides the use of a sulfone compound for stabilizing a peptide in a sample. Also provided is a corresponding method comprising adding a sulfone compound to a sample for stabilizing the peptide. Also provided is a vessel for collecting a sample comprising a peptide, wherein said vessel comprises a sulfone compound. Provided herein is further a composition comprising a peptide and a sulfone compound, a kit comprising a sulfone compound, a vessel of the invention or a composition of the invention. Finally, the present invention also relates to the use of a sulfone compound for inhibiting a protease.

Classes IPC  ?

  • C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase

36.

COBAS ULTRA

      
Numéro de série 99163366
Statut En instance
Date de dépôt 2025-04-30
Propriétaire Roche Diagnostics Operations, Inc. ()
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 10 - Appareils et instruments médicaux

Produits et services

Laboratory instrument for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for use in research, science and industry; computer hardware and downloadable software for use with laboratory instruments, namely, for use in providing automation of laboratory processes, control and monitoring of laboratory instruments, connectivity, data analysis, and data management Medical apparatus for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for medical diagnostic purposes

37.

COBAS TRUE

      
Numéro de série 99163440
Statut En instance
Date de dépôt 2025-04-30
Propriétaire Roche Diagnostics Operations, Inc. ()
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 10 - Appareils et instruments médicaux

Produits et services

Laboratory instrument for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for use in research, science and industry; computer hardware and downloadable software for use in providing automation of laboratory processes, control and monitoring of laboratory instruments, connectivity, data analysis, and data management Medical apparatus for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for medical diagnostic purposes

38.

COBAS CLICK

      
Numéro de série 99163488
Statut En instance
Date de dépôt 2025-04-30
Propriétaire Roche Diagnostics Operations, Inc. ()
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 10 - Appareils et instruments médicaux

Produits et services

Chemical, biochemical and biological reagents for medical and diagnostic purposes; diagnostic reagents for clinical medical and diagnostic purposes; reagents for in-vitro laboratory use for medical purposes Medical apparatus, namely, clinical chemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes

39.

METHOD FOR DIAGNOSING ENDOMETRIOSIS AND FOR CLASSIFYING THE STAGE OF ENDOMETRIOSIS

      
Numéro d'application 18999357
Statut En instance
Date de dépôt 2024-12-23
Date de la première publication 2025-04-24
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Flohr, Aljoscha Michael
  • Georgopoulou, Aikaterini
  • Guennoun, Rym
  • Hund, Martin
  • Klammer, Martin

Abrégé

The present invention relates to methods of diagnosing whether a subject has endometriosis, to methods of classifying the stage of endometriosis, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, and methods of monitoring endometriosis progression in a subject, by determining the amount or concentration of c-Kit in a sample of the subject, and comparing the determined level to a reference value.

Classes IPC  ?

  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

40.

AN IVA TEST UNIT, A TEST SET COMPRISING THE IVA TEST UNIT AND A METHOD OF PRODUCING THE SAME

      
Numéro d'application EP2024078092
Numéro de publication 2025/078295
Statut Délivré - en vigueur
Date de dépôt 2024-10-07
Date de publication 2025-04-17
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Blum, Martin
  • Isgoeren, Yilmaz
  • Meyer Dos Santos, Sascha

Abrégé

IVA test unit (1) comprising: a test strip (2) for detecting an analyte, wherein the test strip comprises at least an application function, a test reaction function and a test detection function; and a housing (3) for storing the test strip (2) wherein the housing (3) comprises an insert tray (4) and an insert hole (5) for inserting the test strip (2) into the insert tray (4), characterized in that the housing (3) is formed as one single piece.

Classes IPC  ?

41.

ELUTION KIT, ANALYTICAL KIT AND METHOD OF ELUTING AND ANALYZING A BIOLOGICAL SAMPLE

      
Numéro d'application EP2024078090
Numéro de publication 2025/078294
Statut Délivré - en vigueur
Date de dépôt 2024-10-07
Date de publication 2025-04-17
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Blum, Martin
  • Isgoeren, Yilmaz
  • Meyer Dos Santos, Sascha

Abrégé

An elution kit (1) for eluting a biological sample in a liquid (2) and dispensing the eluted sample liquid (2') onto a test element (102) of an analytical kit (101), the elution kit (1) comprises: a sample collection swab (3) for collecting the biological sample, wherein the sample collection swab (3) comprises a stick portion (4) for being hand-held and a deformable head portion (5) on the stick portion (4) for collecting the biological sample, wherein the head portion (5) is porous for the liquid (2); and an elution liquid tube (6) which comprises: an interior space (7) for housing the liquid (2), receiving the sample collection swab (3) and eluting the biological sample in the liquid (2); an insertion opening (10) on a first side of the interior space (7) for inserting the sample collection swab (3) into the interior space (7); a dispense opening (11) on a second side of the interior space (7) adjacent the first side for dispensing the eluted sample liquid; a first closure element (12) to seal the dispense opening (11) in a water-vapor impermeable manner; a second closure element (13) to seal the insertion opening (10) in a water-vapor impermeable manner, wherein the first closure element (12) and/or the second closure element (13) comprises a foil; and the liquid (2), wherein the elution liquid tube (6) contains the liquid (2), wherein the interior space (7) is defined by an inner surface (8) that comprises an elution zone (16) with at least one elution portion (9) having a smallest side-to-side distance y ranging between approximately 70% and 140% of a largest side-to-side distance x of the head portion (5) of the sample collection swab (3) and defining a gap (14) through which the sample collection swab (3) can be pushed and pulled in a closed state of the dispense opening (11).

Classes IPC  ?

  • B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
  • B01L 3/02 - BurettesPipettes

42.

REAGENT FORMULATION FOR MASS AXIS CHECK AND ADJUSTMENT

      
Numéro d'application 18694874
Statut En instance
Date de dépôt 2022-09-21
Date de la première publication 2025-04-10
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s) Lang, Robert

Abrégé

The present invention relates to a composition comprising (i) cesium iodide, (ii) ethylamine and/or formic acid, and (iii) methanol and/or water. The present invention further relates to a method for calibrating a mass spectrometry (MS) device comprising (I) determining a mass spectrum of a composition as specified; and (II) calibrating the MS device based on the mass spectrum determined in step (I). The present invention further relates to devices, kits, uses, and methods related thereto.

Classes IPC  ?

  • H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
  • G01N 30/02 - Chromatographie sur colonne
  • G01N 30/72 - Spectromètres de masse

43.

MEANS AND METHODS APPLYING sFlt-1/PIGF OR ENDOGLIN/PIGF RATIO TO RULE OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD

      
Numéro d'application 18798760
Statut En instance
Date de dépôt 2024-08-08
Date de la première publication 2025-04-10
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Hund, Martin
  • Schoedl, Maria

Abrégé

The present invention concerns the field of diagnostic assays for prenatal diagnosis of preeclampsia. In particular, it relates to a method for diagnosing whether a pregnant subject is not at risk for preeclampsia within a short window of time comprising a) determining the amount of at least one angiogenesis biomarker selected from the group consisting of sFlt-1, Endoglin and PlGF in a sample of said subject, and b) comparing the amount with a reference, whereby a subject being not at risk for developing preeclampsia within a short period of time is diagnosed if the amount is identical or decreased compared to the reference in the cases of sFlt-1 and Endoglin and identical or increased in the case of PlGF, wherein said reference allows for making the diagnosis with a negative predictive value of at least about 98%. Further contemplates are devices and kits for carrying out said method.

Classes IPC  ?

  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
  • G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
  • G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients

44.

METHODS FOR MANAGEMENT OF PROSTATE CANCER

      
Numéro d'application 18908787
Statut En instance
Date de dépôt 2024-10-07
Date de la première publication 2025-04-10
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Cobbaert, Christa
  • Kroeniger, Konstantin
  • Lageveen-Kammeijer, Guinevere
  • Nouta, Jan
  • Rolny, Vinzent
  • Ruhaak, Renee
  • Swiatek-De Lange, Magdalena
  • Tabares, Gloria
  • Van Der Burgt, Yuri
  • Wuhrer, Manfred

Abrégé

The present invention relates to methods for assessing whether or not a patient has aggressive prostate cancer by determining the levels of particular glycoforms attached to prostate specific antigen (PSA) protein in a biofluid sample of a subject, and comparing the determined level or concentration to a reference. The methods are particularly useful for assessing subjects that have 2-10 ng/ml total PSA in the subject's serum.

Classes IPC  ?

  • G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
  • G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes

45.

COBAS LUMIRA

      
Numéro de série 99117674
Statut En instance
Date de dépôt 2025-04-02
Propriétaire Roche Diagnostics Operations, Inc. ()
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 10 - Appareils et instruments médicaux

Produits et services

Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes; all of the foregoing excluding active pharmaceutical ingredients, isotopes and radioisotopes Analyzers for the analysis of biological samples for medical diagnostic purposes; in vitro diagnostic devices in the nature of biosensors for the detection and analysis of medically significant analytes in biological samples for medical purposes

46.

DETERMINING LIKELIHOOD OF KIDNEY FAILURE

      
Numéro d'application 18728195
Statut En instance
Date de dépôt 2023-01-24
Date de la première publication 2025-03-27
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Danzer, Carsten
  • Emons, Martin Josef
  • Klammer, Martin
  • Sillitoe, Nicolas Seungoon
  • Triunfo, Riccardo

Abrégé

A computer-implemented method is provided, which determines at a prediction time tp, a likelihood of kidney failure of a patient within an amount of time Δt. The method comprises receiving input data, the input data comprising a recent creatinine level cR or recent eGFR eGFRR, and one or more of the following: (a) an initial creatinine level c0 and either: a time t0 at which the initial creatinine level c0 was measured, or a time interval ΔT0=tp−t0; (b) an initial estimated glomerular filtration rate (eGFR) eGFR0 and either: a time t0 at which the initial eGFR was determined, or a time interval ΔT0=tp−t0; (c) for a plurality of past creatinine level measurements ci measured at a respective times ti, a statistical parameter derived from a linear regression of the plurality of past creatinine level measurements; and (d) for a plurality of past eGFR values eGFRi determined at respective times ti, a statistical parameter derived from a linear regression of the plurality of past eGFR values; and applying a machine-learning model to the input data to generate an output indicating the likelihood of kidney failure within the given amount of time Δt. Corresponding training methods and systems are also provided.

Classes IPC  ?

  • A61B 5/20 - Mesure des fonctions urologiques
  • A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
  • G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
  • G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

47.

THERMAL CONTROL DEVICE FOR TEMPERATURE CYCLING, METHOD FOR CONTROLLING TEMPERATURE CYCLING USING A THERMAL CONTROL DEVICE, AND SYSTEM FOR CONTROLLING TEMPERATURE OF A SAMPLE USING A THERMAL CONTROL DEVICE

      
Numéro d'application EP2024076377
Numéro de publication 2025/061910
Statut Délivré - en vigueur
Date de dépôt 2024-09-20
Date de publication 2025-03-27
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Fischer, Simon
  • Sangermano, Marco
  • Wiget, Pascal

Abrégé

In one embodiment, a thermal control device (110) adapted for temperature cycling is provided. The thermal control device (110) comprises a thermally conductive heat spreader layer (118) comprising a first side surface and a second side surface. A heater circuit (120) is disposed adjacent to and in thermal contact with at least one of the first side surface and the second side surface of the thermally conductive heat spreader layer (118). At least one thermal interface material layer (114) is disposed adjacent to and in thermal contact with one of the first side surface and the second side surface of the thermally conductive heat spreader layer (118). A cooling block (116) is disposed adjacent to and in thermal contact with the thermal interface material layer (114). The cooling block (116) is adapted to conduct heat energy away from the thermally conductive heat spreader layer (118). A controller is coupled to and adapted to control the heater circuit (120). In another embodiment, a diagnostic test device is provided.

Classes IPC  ?

  • B01L 7/00 - Appareils de chauffage ou de refroidissementDispositifs d'isolation thermique

48.

CLASSIFICATION METHOD FOR CLASSIFYING SYSTEMIC INFLAMMATORY STATES

      
Numéro d'application EP2024075599
Numéro de publication 2025/056737
Statut Délivré - en vigueur
Date de dépôt 2024-09-13
Date de publication 2025-03-20
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Bundschus, Markus
  • Schoedl, Thomas
  • Wohlfart, Christian

Abrégé

A computer-implemented training method (110) of training at least one trainable model is disclosed for classifying a patient's health condition into a systemic inflammatory state (168, 170, 172) selected from a predetermined group of at least three systemic inflammatory states (168, 170, 172). The method comprises: a. providing the trainable model; b. retrieving labeled training patient data, the training patient data comprising gene expression data of patients having known systemic inflammatory states (168, 170, 172); and c. training the trainable model on the labeled training patient data. Further disclosed is a computer-implemented classification method (112) of classifying a patient's health condition into a systemic inflammatory state (168, 170, 172) selected from a predetermined group of at least three systemic inflammatory states (168, 170, 172) and systems, computer programs and computer-readable storage media for performing the methods.

Classes IPC  ?

  • G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
  • G16B 40/20 - Analyse de données supervisée
  • G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

49.

METHOD FOR ASSESSING SYSTEMIC INFLAMMATION

      
Numéro d'application EP2024075667
Numéro de publication 2025/056769
Statut Délivré - en vigueur
Date de dépôt 2024-09-13
Date de publication 2025-03-20
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Bundschus, Markus
  • Schoedl, Thomas
  • Wohlfart, Christian

Abrégé

The present invention relates to the field of diagnostics. In particular, it relates to a method for assessing systemic inflammation in a subject exhibiting symptoms thereof comprising a) determining in a sample of said subject the amounts of biomarkers from a group of biomarkers selected from i) a first group of biomarkers comprising: POMK, NEK6, KCNA5, LARGE2, ZNF425, NACA2, CFAP57, SPINT1, ZNF492, and S100A6, ii) a second group of biomarkers comprising: NEK6, SRPK3, TNFSF8, S100A6, NMUR1, DHFR, HIST1H4D, ZDHHC4, TRAF3, and SGMSlor iii) a third group of biomarkers comprising: C9orfl35, ZNF425, ACOT4, SPDYA, DAPP1, LY86, ZPBP2, RPL3L, UPK1B, and APBB3, b) comparing said determined amounts of biomarkers from said group of biomarkers to a reference, and c) assessing systemic inflammation in the subject. Further, the present invention, in general, relates to the use of the amounts of said biomarkers in a sample of a subject exhibiting symptoms of systemic inflammation for assessing systemic inflammation. Moreover, contemplated are a device and a kit for assessing systemic inflammation.

Classes IPC  ?

  • C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

50.

LABORATORY DEVICE AND LABORATORY SYSTEM

      
Numéro d'application EP2024074823
Numéro de publication 2025/051852
Statut Délivré - en vigueur
Date de dépôt 2024-09-05
Date de publication 2025-03-13
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s) Eicher, Patrick

Abrégé

The invention relates to a laboratory device (1) for handling laboratory sample container racks (50), the laboratory device (1) comprising a base (2) extending horizontally, the base (2) being adapted to support laboratory sample container racks (50) placed thereon, a first finger (3) being movable relative to the base (2), the first finger (3) being adapted to position a laboratory sample container rack (50) on the base (2), a second finger (4) being adapted to horizontally counteract the first finger (3) so that the laboratory sample container rack (50) positioned on the base (2) is holdable in between the first finger (3) and the second finger (4), a down-holder (5) being movable relative to the base (2), the down-holder (5) being adapted to releasably vertically secure the laboratory sample container rack (50) positioned on the base (2), and a linkage (6) which motion-couples the first finger (3) and the second finger (4) and the down-holder (5) to one another.

Classes IPC  ?

  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
  • B01L 9/06 - Supports de tubes à essaiPorte-tubes à essai
  • B65G 65/00 - Chargement ou déchargement
  • G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
  • G01N 35/04 - Détails du transporteur

51.

METHOD FOR CHARACTERIZATION OF A MASS SPECTROMETRY INSTRUMENT COMPRISING AT LEAST ONE MASS ANALYZING CELL

      
Numéro d'application 18719252
Statut En instance
Date de dépôt 2022-12-13
Date de la première publication 2025-02-27
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Quint, Stefan
  • Schweinberger, Florian
  • Tiemann, Benjamin
  • Wagner, Marius

Abrégé

A method for characterization of a mass spectrometry instrument (100) comprising at least one mass analyzing cell (102, 104, 106) is proposed. The method comprising the steps of analyzing a sample (110) comprising at least one substance having a known molecular weight by means of the mass spectrometry instrument (100) so as to provide a mass spectrum (116, 118, 144, 146) of the sample (110), determining an outer envelope and an inner envelope of the mass spectrum (116, 118, 144, 146), calculating a squared difference between the outer envelope and the inner envelope, and determining a deviation of the calculated squared difference from a theoretical mass to charge ratio value of the substance.

Classes IPC  ?

  • H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules

52.

METHOD FOR OPERATING LABORATORY SYSTEM AND LABORATORY SYSTEM

      
Numéro d'application 18726309
Statut En instance
Date de dépôt 2022-12-20
Date de la première publication 2025-02-27
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Lambaek, Ole
  • Schnarwiler, Dominik
  • Taeymans, Bert

Abrégé

A method for operating a laboratory system having a plurality of sample containers; a plurality of laboratory devices to handle the sample containers, the sample containers being assigned for handling to the target device; and a control device configured to control assignment of the sample containers to the target devices; and assigning the sample containers. The assigning comprises: determining a target device workload state for each target device, the workload state being between a first range limit and a second range limit, and determined according to a metric being proportional to a resource target device state indicative of sample containers assigned to the target device, and a power of an output flow of the target device, assigning the sample containers to the target devices according to the target device workload states; and providing sample containers to the plurality of target devices. Furthermore, a laboratory system is provided.

Classes IPC  ?

  • G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
  • G06Q 10/0631 - Planification, affectation, distribution ou ordonnancement de ressources d’entreprises ou d’organisations
  • G06Q 10/0639 - Analyse des performances des employésAnalyse des performances des opérations d’une entreprise ou d’une organisation

53.

METHOD FOR OPERATING A SORTER DEVICE IN AN IVD LABORATORY SYSTEM AND IVD LABORATORY SYSTEM

      
Numéro d'application 18941549
Statut En instance
Date de dépôt 2024-11-08
Date de la première publication 2025-02-27
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Lambaek, Ole
  • Schesny, Andreas

Abrégé

The present disclosure refers to a method for operating a sorter device in an IVD laboratory system, the method comprising providing a sorter device in an IVD laboratory system provided with a system operation controller, the sorter device having a plurality of sample container racks each provided with reception holes for receiving sample containers, a handling device configured to pick sample containers from and place sample containers in the reception holes of the sample container racks, a sorter device controller configured to control operation of the sorter device and connectable to the system operation controller, and an output device functionally connected to the sorter device controller and configured to output at least one of audio data and video data. The sorter device is configured in a pre-operation process, the configuring comprising: assigning the plurality of sample container racks to a plurality of processing sub-targets conducted by the IVD laboratory system in operation, wherein a first sample container rack is assigned to a first processing sub-target and a second sample container rack is assigned to a second processing sub-target which is different from the first processing sub-target, and assigning to the first sample container rack a first threshold value indicative of a first threshold number of sample containers in the first sample container rack, wherein the first threshold number of sample containers is smaller than a maximum number of sample containers receivable in the first sample container rack. The sorter device is operated in an operation process, the operating comprising: placing sample containers in the reception holes of the first sample container rack by the handling device, determining a first present number of sample containers received in the first sample container rack by the sorter device controller, comparing the first present number of sample containers to the first threshold value by the sorter device controller, and if the first present number of sample containers is equal to or greater than the first threshold value, outputting a first warning data through the output device. Furthermore, an IVD laboratory system is provided.

Classes IPC  ?

  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
  • G01N 35/04 - Détails du transporteur

54.

Sensor for detecting a plurality of analytes

      
Numéro d'application EP2024073193
Numéro de publication 2025/040616
Statut Délivré - en vigueur
Date de dépôt 2024-08-19
Date de publication 2025-02-27
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Amann-Zalan, Ildiko
  • Gutiérrez-Sanz, Oscar
  • Lopez-Calle, Eloisa
  • Probst, Christopher
  • Wagner, Robin

Abrégé

There is disclosed a method and sensor for detecting a plurality of analytes in bodily fluid, the sensor comprising electrodes including a first working electrode, a second working electrode, a third working electrode, a counter electrode, and a reference electrode; wherein the first working electrode is configured to detect a first signal indicative of a first analyte concentration using potentiometry; wherein the second working electrode is configured to detect a second signal indicative of a second analyte concentration using amperometry; wherein the third working electrode is configured to detect a third signal indicative of a third analyte concentration using amperometry; wherein the first analyte, the second analyte, and third analyte are different analytes; wherein the first signal, the second signal, and the third signal are detected using the same reference electrode; wherein at least part of the detection of the first signal occurs simultaneously with the detection of the second signal; wherein the second signal and third signal are detected using the same counter electrode; wherein at least part of the detection of the second signal occurs simultaneously with the detection of the third signal; and wherein at least one of the second working electrode and third working electrode is continuously polarized by application of a polarization voltage during detection of the first signal, second signal and third signal.

Classes IPC  ?

  • A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
  • A61B 5/1468 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques
  • G01N 27/27 - Association de plusieurs systèmes ou cellules de mesure, chacun mesurant un paramètre différent, dans laquelle les résultats des mesures peuvent être, soit utilisès indépendamment, les systèmes ou les cellules étant physiquement associés, soit combinés pour produire une valeur représentative d'un autre paramètre
  • G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
  • G01N 33/70 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir la créatine ou la créatinine
  • G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
  • A61B 5/1495 - Étalonnage ou test des sondes in vivo
  • G01N 33/62 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir l'urée
  • G01N 33/64 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des cétones
  • G01N 33/98 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir de l'alcool, p. ex. de l'éthanol dans l'haleine

55.

METHOD FOR PREPARING ACID RESISTANT MAGNETIC PARTICLES AND ACID RESISTANT MAGNETIC PARTICLES

      
Numéro d'application 18713584
Statut En instance
Date de dépôt 2022-11-23
Date de la première publication 2025-02-27
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Silvestre, Martin Eduardo
  • Eisold, Sabine
  • Heindl, Dieter
  • Peters, Kristina

Abrégé

In a first aspect, the invention relates to a method for preparing a magnetic bead comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers, the method comprising steps (a) to (d), wherein at least one of steps (b), (c) and (d) is/are done under sonication, wherein sonication is done with an amplitude (peak-to-peak) in the range of from 50 to 250 μm. A second aspect of the invention is related to a magnetic bead comprising (i) at least one magnetic particle (M) and (ii) a silica coating, wherein the silica coating comprises at least two silica layers; wherein the magnetic bead is stable against 7.5 M hydrochlorid acid and has a metal (cation) leaching rate in 7.5 M hydrochloric acid in the range of from 0.1 to 10%, wherein the metal (cation) leaching is determined according to a complex formation of Fe2+ with bathophenanthroline according to Reference Example 8.2. In a third aspect, the invention relates to a functionalized magnetic bead comprising at least one, magnetic bead according to the second aspect, wherein an outer silica layer is functionalized with at least one group selected from the group consisting of amino group, azide group, alkyne group, carboxyl group, thiol group, epoxy group, aryl group and alkyl group. A fourth aspect of the invention is directed to a process for functionalizing a magnetic bead according to the second aspect comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers. A fifth aspect of the invention is related to a method for preparing magnetic Fe3O4 supra particles and a sixth aspect relates to the use of a magnetic bead according to the second aspect or of a functionalized according to the fourth aspect for immobilization of acid stable biocatalysts or for solid-phase organic synthesis using acid-stable linker.

Classes IPC  ?

  • H01F 1/33 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques en matériaux inorganiques caractérisés par leur coercivité en matériaux magnétiques doux mélanges de particules métalliques ou non métalliquesAimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques en matériaux inorganiques caractérisés par leur coercivité en matériaux magnétiques doux particules métalliques ayant un revêtement d'oxyde
  • H01F 1/00 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques
  • H01F 1/34 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques en matériaux inorganiques caractérisés par leur coercivité en matériaux magnétiques doux substances non métalliques, p. ex. ferrites

56.

METHOD OF CONTROLLING THE FUNCTIONALITY OF AN ANALYTICAL SYSTEM

      
Numéro d'application EP2024073252
Numéro de publication 2025/040642
Statut Délivré - en vigueur
Date de dépôt 2024-08-20
Date de publication 2025-02-27
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
Inventeur(s) Juergens, Ludger Herbert Joachim

Abrégé

A method of controlling the functionality of an analytical system (110) is disclosed. The method comprises: a. providing at least one container (114) containing at least one control fluid, the container (114) comprising at least one identifier (124), wherein the identifier (124) comprises at least one identification number of the container (114); b. reading the identifier (124) of the container (114) by using at least one reading device (113) of the analytical system (110); and c. performing a database query in a database (116) of the analytical system (110), the database (116) containing database entries (130) for a plurality of known containers (114) comprising identification numbers of the known containers (114) and assigned expiry information for the respective known containers (114), the database query comprising checking if the container (114) already has a database entry (130) in the data- base (116). Further, an analytical system (110) comprising at least one analytical device (112) for determining an analyte concentration in a sample of a bodily fluid is disclosed.

Classes IPC  ?

  • G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
  • G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p. ex. pour planifier la maintenance ou les mises à jour
  • G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
  • G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
  • A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

57.

ELECTROCHEMICAL IMMUNOASSAY

      
Numéro d'application EP2024073570
Numéro de publication 2025/040753
Statut Délivré - en vigueur
Date de dépôt 2024-08-22
Date de publication 2025-02-27
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Gutierrez-Sanz, Oscar
  • Lopez-Calle, Eloisa
  • Osterheld, Hanna
  • Thakur, Bhawana
  • Treu, Tabea

Abrégé

There is disclosed an electrode for an electrochemical immunoassay; wherein the electrode is functionalized with at least one antibody or fragment thereof configured to bind to at least one analyte; and wherein the at least one antibody or fragment thereof is conjugated with at least one redox species such that the electrochemical activity of the at least one redox species is altered when the at least one antibody or fragment thereof binds to the at least one analyte.

Classes IPC  ?

  • G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

58.

MONITORING OF CARDIOVASCULAR MARKERS IN INTERSTITIAL FLUID AND ITS APPLICATION IN ASSESSMENT OF HEART FAILURE

      
Numéro d'application EP2024073571
Numéro de publication 2025/040754
Statut Délivré - en vigueur
Date de dépôt 2024-08-22
Date de publication 2025-02-27
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Gutierrez-Sanz, Oscar
  • Lopez-Calle, Eloisa
  • Amann-Zalan, Ildiko

Abrégé

The present invention relates to methods of assessing heart failure (HF), determining the risk of developing HF, monitoring HF, classifying HF, risk stratification and prognosis in patients with HF and determining the therapeutic effect of a treatment regimen for HF in a subject by determining the level of one or more cardiac related (poly)peptide biomarkers in the interstitial fluid (ISF) from the subject, and comparing the determined level to a reference value. Further this invention refers to the use of ISF in the methods described herein.

Classes IPC  ?

  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

59.

METHOD AND LABORATORY SYSTEM FOR DETERMINING AT LEAST ONE CONTAINER INFORMATION ABOUT A LABORATORY SAMPLE CONTAINER

      
Numéro d'application 18935834
Statut En instance
Date de dépôt 2024-11-04
Date de la première publication 2025-02-20
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Rein, Michael
  • Wiegand, Friederike

Abrégé

A method is provided for determining at least one container information (coi) about a laboratory sample container, wherein the method comprises the steps: a) acquiring an image (ibc) comprising a brightness and/or color information (bci) of a possible region of the container, b) acquiring a map (md) comprising a depth information (di) of the region, and c) determining the container information (coi) by fusing the brightness and/or color information (bci) and the depth information (di).

Classes IPC  ?

  • B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
  • G06V 10/80 - Fusion, c.-à-d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification
  • G06V 20/64 - Objets tridimensionnels

60.

POSITION TRACKING SYSTEM AND METHOD FOR TRACKING A RELATIVE POSITION OF CONNECTED MODULES

      
Numéro d'application 18937855
Statut En instance
Date de dépôt 2024-11-05
Date de la première publication 2025-02-20
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Leontjevs, Vladimirs
  • Riedel, Philipp

Abrégé

A position tracking system for tracking a relative position between connected modules. A target is arrangeable on and/or within a first connected module, the connected modules mechanically interacting for transporting objects between modules; a position sensor is arrangeable on and/or within a second connected module and is configured for generating a sensor signal according to a relative position between the position sensor and target, a processing unit configured for tracking a relative position between the connected modules from the sensor signal; and a second sensor is configured for generating a second sensor signal according to at least a second parameter, wherein the second sensor is a temperature sensor and/or a humidity sensor, the processing unit being configured for considering the second sensor signal when determining the relative position between the connected modules. Further disclosed are related monitoring systems and methods for tracking and monitoring at least two connected modules.

Classes IPC  ?

  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet

61.

METHOD OF HANDLING LABORATORY SAMPLE CONTAINERS AND APPARATUS FOR HANDLING LABORATORY SAMPLE CONTAINERS

      
Numéro d'application 18927356
Statut En instance
Date de dépôt 2024-10-25
Date de la première publication 2025-02-13
Propriétaire Roche Diagnostics Opereations, Inc. (USA)
Inventeur(s)
  • Baltasar Badaya, Raul
  • Baumgart, Julian

Abrégé

A method of handling laboratory sample containers is presented. The method comprises moving a laboratory sample container to a target position. The target position is a position at which the laboratory sample container is inserted into a corresponding orifice of a laboratory sample container rack provided that the laboratory sample container rack is placed at an intended position. The laboratory sample container is prevented from moving horizontally more than a predetermined horizontal distance if inserted into the corresponding orifice of the laboratory sample container rack. The method also comprises applying a force in a horizontal direction (xy) to the laboratory sample container, determining if the laboratory sample container moves in the horizontal direction (xy) more than the predetermined horizontal distance, and performing an error procedure if it is determined that the laboratory sample container moves in the horizontal direction (xy) more than the predetermined horizontal distance.

Classes IPC  ?

  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
  • G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
  • G01N 35/04 - Détails du transporteur

62.

NOVEL ANTI-THYMIDINE KINASE ANTIBODIES

      
Numéro d'application 18772484
Statut En instance
Date de dépôt 2024-07-15
Date de la première publication 2025-02-06
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Duefel, Hartmut
  • Engel, Alfred
  • Kroner, Frank
  • Meier, Thomas
  • Rutz, Sandra
  • Schraeml, Michael
  • Tabares, Gloria
  • Kurtkaya, Ulrike
  • Pinchuk, Boris
  • Zimmermann, Christina

Abrégé

The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1

Classes IPC  ?

  • C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
  • G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

63.

SERUM EPHA1 AS BIOMARKER FOR ENDOMETRIOSIS

      
Numéro d'application EP2024071268
Numéro de publication 2025/026908
Statut Délivré - en vigueur
Date de dépôt 2024-07-26
Date de publication 2025-02-06
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Allegranza, Deirdre Mary
  • Flohr, Aljoscha Michael
  • Hund, Martin
  • Klammer, Martin

Abrégé

The present invention relates to methods of diagnosing whether a subject has endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, and methods of monitoring endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain progression in a subject, by determining the amount or concentration of EphA1 in a sample of the subject, and comparing the determined level to a reference value.

Classes IPC  ?

  • G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
  • G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

64.

MONOCLONAL ANTIBODIES SPECIFIC FOR SARS-COV-2 RBD

      
Numéro d'application 18704654
Statut En instance
Date de dépôt 2022-10-25
Date de la première publication 2025-02-06
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Gerg, Michael
  • Jochum, Simon
  • Jucknischke, Ute
  • Kurtkaya, Ulrike
  • Schraeml, Michael
  • Stiegler, Sandrine Carolina

Abrégé

The present invention relates to monoclonal antibodies binding to the Receptor Binding Domain of the Spike protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, method of detecting SARS-CoV-2 virus in a sample comprising using said antibodies and methods of using said antibodies in immunoassays.

Classes IPC  ?

  • C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

65.

BLAST CELL CLASSIFICATION

      
Numéro d'application 18723851
Statut En instance
Date de dépôt 2022-12-23
Date de la première publication 2025-02-06
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Bruenggel, Nils
  • Conway, Patrick
  • Davidson, Simon John
  • Dejean, Emilie
  • Gildenblat, Jacob
  • Sagiv, Chen
  • Vallotton, Pascal

Abrégé

A computer-implemented method of differentiating between lymphoid blast cells and myeloid blast cells comprises: receiving a digital image containing one or more blast cells; applying a parametric model classifier to one or more portions of the digital image each containing a respective blast cell, the parametric model configured to generate an output indicative of whether each blast cell is a lymphoid blast cell or a myeloid blast cell. Computer-implemented methods of training a parametric model are also provided, as well as a clinical decision support system relying on the computer-implemented method of classifying blast cells.

Classes IPC  ?

  • G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
  • G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
  • G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients

66.

FEDERATED LEARNING OF MEDICAL VALIDATION MODEL

      
Numéro d'application 18696634
Statut En instance
Date de dépôt 2021-11-01
Date de la première publication 2025-01-30
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Yao, Yi
  • Xing, Wei Bin
  • Tao, Xiao Jun
  • Qian, Jing
  • Zhou, Qi
  • Zhang, Chenxi
  • Qian, Yin

Abrégé

A computer-implemented method is provided that includes transmitting, by a master node to a plurality of computing nodes, definition information about an initial medical validation model (410): performing, by the master node, a federated learning process together with the plurality of computing nodes (420), to jointly train the initial medical validation model using respective processed local training datasets available at the plurality of computing nodes, the respective local training datasets being processed by the plurality of computing nodes based on the definition information; and determining, by the master node, a final medical validation model based on a result of the federated learning process (430). Through the solution, by means of federated learning, it addresses the data security and privacy concerns from local sites owning.

Classes IPC  ?

  • G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
  • G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
  • G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
  • H04W 84/02 - Réseaux pré-organisés hiérarchiquement, p. ex. réseaux de messagerie, réseaux cellulaires, réseaux locaux sans fil [WLAN Wireless Local Area Network] ou boucles locales sans fil [WLL Wireless Local Loop]

67.

MR-PROADM MARKER PANELS FOR EARLY DETECTION OF SEPSIS

      
Numéro d'application 18696730
Statut En instance
Date de dépôt 2022-09-28
Date de la première publication 2025-01-30
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Gruenewald, Felix
  • Jeger, Victor Johann Raul
  • Klammer, Martin
  • Schuetz, Philipp
  • Von Holtey, Maria
  • Weber, Stephen
  • Wegmeyer, Heike
  • Wienhues-Thelen, Ursula-Henrike

Abrégé

The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being MR-proADM, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFlt-1, GDF15 and ESM1, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being MR-proADM and a second biomarker selected from the group consisting of: sFlt-1, GDF15 and ESM1, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

Classes IPC  ?

  • G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

68.

SINGLE-USE DISPENSER, DISPENSER-ARRANGEMENT, USE OF A BLOW-MOLDED VESSEL, AND USE OF A SINGLE-USE DISPENSER

      
Numéro d'application EP2024070428
Numéro de publication 2025/021649
Statut Délivré - en vigueur
Date de dépôt 2024-07-18
Date de publication 2025-01-30
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s) Jürgens, Ludger Herbert Joachim

Abrégé

The invention relates to a single-use dispenser (1) for supplying a control liquid (L) to an analytical device, the single-use dispenser (1) comprising a blow-molded vessel (2) fluid-tightly delimiting an interior volume (3), and a volume (4) of the control liquid (L), wherein the volume (4) of the control liquid (L) is stored within the interior volume (3), and wherein the blow-molded vessel (2) has a predetermined breaking point (5) adapted to form an outlet aperture (8) for the control liquid (L) by breaking the blow-molded vessel (2) in its predetermined breaking point (5).

Classes IPC  ?

  • B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
  • A61J 1/06 - Ampoules ou cartouches
  • B65D 1/09 - Ampoules

69.

SCREENING METHODS FOR ANTIBODY COMPOSITIONS

      
Numéro d'application EP2024070419
Numéro de publication 2025/017135
Statut Délivré - en vigueur
Date de dépôt 2024-07-18
Date de publication 2025-01-23
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Ofenloch-Haehnle, Beatus
  • Jochum, Simon

Abrégé

The present invention provides a screening method for obtaining an antibody composition comprising at least two different monoclonal antibodies. The invention also relates to said antibody composition, and its use. Further, the invention provides a kit comprising said antibody composition. The invention also provides a method for determining a level of antibodies directed to an antigen in a sample.

Classes IPC  ?

  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
  • G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
  • G01N 33/96 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir un étalon de contrôle du sang ou du sérum

70.

METHODS FOR DETERMINING MS REAGENT PARAMETERS VIA LEACHABLE COMPOUNDS

      
Numéro d'application EP2024070440
Numéro de publication 2025/017144
Statut Délivré - en vigueur
Date de dépôt 2024-07-18
Date de publication 2025-01-23
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s) Schweinberger, Florian Frank

Abrégé

The present invention relates to a method for determining a mass spectrometry (MS) reagent stored in a storage container for a period of time and/or at least one storage parameter thereof, said method comprising (a) determining at least one leachable compound of said storage container; (b) comparing the at least one leachable compound determined in step (a) to a reference, and (c) determining said MS reagent and/or at least one storage parameter thereof based on the comparing in step (b); The present invention also relates to a method of quality assurance of an MS analysis, to a data carrier, an MS system, and a kit related thereto.

Classes IPC  ?

  • H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
  • G01N 30/06 - Préparation

71.

AUTOMATIC ANALYZER

      
Numéro d'application 18711999
Statut En instance
Date de dépôt 2022-11-14
Date de la première publication 2025-01-23
Propriétaire
  • HITACHI HIGH-TECH CORPORATION (Japon)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Hamasaki, Koshin
  • Takada, Eiichiro
  • Saito, Yoshiaki
  • Kobel, Stefan
  • Haberhausen, Gerd
  • Voelker, Markus
  • Foster, Elisabeth

Abrégé

An automatic analyzer 101 includes a judgment part 118f which descends a probe 201 in the direction of a reagent 205 and suspends the downward movement of the probe 201 at a first position PT higher than a liquid level value P0 assumed to be a height of a liquid level by a first predetermined value Db. The judgment part 118f determines that the reagent 205 is in a normal state when the liquid level is not detected by an electrostatic capacity sensor 206 at the first position PT. Further, the judgment part 118f determines that the reagent 205 in an abnormal state when the liquid level is detected by the electrostatic capacity sensor 206 before reaching the first position PT. An automatic analyzer capable of reducing consumption of consumables produced at the time of reagent registration compared with conventional cases is provided.

Classes IPC  ?

  • G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection

72.

DSFV AS AN IGG FRAGMENT FORMAT AND METHODS OF PRODUCTION AND LABELLING THEREOF

      
Numéro d'application EP2024070463
Numéro de publication 2025/017153
Statut Délivré - en vigueur
Date de dépôt 2024-07-18
Date de publication 2025-01-23
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Bartl, Andrea
  • Hemann, Matthias
  • Kunzelmann, Stefan
  • Meier, Thomas
  • Mohamed, Mohamed Yosry Hassan
  • Oelschlaegel, Tobias
  • Roesser, Alisa
  • Schraeml, Michael
  • Sieber, Laura

Abrégé

The present invention relates to antibodies and antigen-binding fragments thereof, in particular (ds)Fv fragments. The invention also relates to methods of producing these antibodies and fragments thereof as well as their uses and corresponding polynucleotides and kits comprising the same.

Classes IPC  ?

  • C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
  • C07K 16/26 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des hormones

73.

RATIOS OF sFlt-1 TO P1GF OR ENDOGLIN TO P1GF AS BIOMARKERS FOR PREECLAMPSIA RELATED ADVERSE OUTCOMES AFTER BIRTH

      
Numéro d'application 18902725
Statut En instance
Date de dépôt 2024-09-30
Date de la première publication 2025-01-16
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Hund, Martin
  • Dieterle, Thomas
  • Lapaire, Olav

Abrégé

The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.

Classes IPC  ?

  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

74.

Carry case for handheld medical meter

      
Numéro d'application 29841718
Numéro de brevet D1057393
Statut Délivré - en vigueur
Date de dépôt 2022-06-08
Date de la première publication 2025-01-14
Date d'octroi 2025-01-14
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Arnold, Peter
  • Frontzek, Carolin
  • Galbraith, Sofia Elisabeth
  • Gebhard, Roman

75.

METHOD FOR DETERMINING LIFETIME OF AT LEAST ONE CHROMATOGRAPHY COLUMN

      
Numéro d'application 18294945
Statut En instance
Date de dépôt 2022-08-01
Date de la première publication 2025-01-02
Propriétaire ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Laubender, Ruediger
  • Quint, Stefan
  • Wagner, Marius

Abrégé

A computer implemented method (140) for determining lifetime of at least one chromatography column (116) of at least one chromatography device (110), wherein the method (140) comprises the following steps: i) receiving model input chromatography data via at least one communication interface (128); ii) determining at least one state variable indicative of lifetime of the chromatography column (116) using at least one data driven model based on the model input chromatography data using at least one processing device (130); iii) evaluating the determined state variable thereby determining information about lifetime by using the processing device (130), wherein the evaluation comprises comparing the determined state variable to at least one threshold. A computer implemented method (140) for determining lifetime of at least one chromatography column (116) of at least one chromatography device (110), wherein the method (140) comprises the following steps: i) receiving model input chromatography data via at least one communication interface (128); ii) determining at least one state variable indicative of lifetime of the chromatography column (116) using at least one data driven model based on the model input chromatography data using at least one processing device (130); iii) evaluating the determined state variable thereby determining information about lifetime by using the processing device (130), wherein the evaluation comprises comparing the determined state variable to at least one threshold. Further, a test system (112), a computer program and a method for operating a chromatography column (116) are disclosed.

Classes IPC  ?

76.

DETECTION OF AIR BUBBLES IN OPTICAL DETECTION UNIT

      
Numéro d'application 18755464
Statut En instance
Date de dépôt 2024-06-26
Date de la première publication 2024-12-26
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Hildenbrand, Juergen
  • Kramlich, Alexander
  • Lambertson, Michael

Abrégé

An in-vitro diagnostic (IVD) analyzer 200 comprising an optical detection unit 217 comprising a cuvette 214 for the optical measurement of a biological sample 2, 2′ is herein disclosed. The IVD analyzer 200 further comprises a piezo actuator 218 arranged on one side of the cuvette 214 configured to transmit ultrasonic waves 254, 254′ through the cuvette 214, a piezo receiver 218′ arranged on the opposite side of the cuvette 214 configured to receive ultrasonic waves 255, 255′, 255″ transmitted through the cuvette 214 and a controller 250 configured to operate according to either a lysis operating mode (L) or an air-detection operating mode (AD). According to the lysis operating mode (L) the piezo actuator 218 is configured to transmit ultrasonic waves 254′ through the cuvette 214 for disrupting cellular particles contained in the biological sample 2. According to the air-detection operating mode (AD) the piezo actuator 218 is configured to transmit ultrasonic waves 254 through the cuvette 214 and the controller 250 is configured to correlate changes in amplitude and/or shifts of phase of the ultrasonic waves 255, 255′, 255″ received by the piezo receiver 218′ relative to reference values with an eventual presence and quantity of air 3 in the cuvette 214, in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air 3. A respective automated method of operating the in-vitro diagnostic analyzer 200 in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air is herein also disclosed.

Classes IPC  ?

  • G01N 21/94 - Recherche de souillures, p. ex. de poussières

77.

METHOD FOR IMPROVING CROSS-FLOW FILTRATION AND CROSS-FLOW FILTRATION SYSTEM

      
Numéro d'application 18810797
Statut En instance
Date de dépôt 2024-08-21
Date de la première publication 2024-12-12
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Munoz, Carlos
  • Zahn, Hans

Abrégé

A method of cross-flow filtering wastewater from a diagnostic apparatus or a laboratory analyser, wherein the wastewater comprises nanoparticles and/or microparticles, and the wastewater is streaming in a laminar flow across a surface of a filter membrane, the method comprising: (a) streaming the wastewater across the surface of the filter membrane with a flow rate, so that the flow of the wastewater is a laminar flow with a Reynolds number (Re) of smaller than 500; (b) streaming the wastewater in pulse cycles across the surface of the filter membrane, wherein each pulse cycle comprises one active phase in which the wastewater is under a duty pressure and one inactive phase in which the wastewater is under an inactive pressure, wherein the inactive pressure is no more than 10% of the duty pressure and the active phases have a duration of greater than 50% of the corresponding pulse cycles; and (c) separating the nanoparticles and/or microparticles from the wastewater when the wastewater passes through the filter membrane. Also described is a cross-flow filtration system configured for performing the method.

Classes IPC  ?

  • C02F 1/00 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout
  • C02F 103/00 - Nature de l'eau, des eaux résiduaires ou des eaux ou boues d'égout à traiter

78.

HEALTHCARE DATA SYSTEM

      
Numéro d'application 18421536
Statut En instance
Date de dépôt 2024-01-24
Date de la première publication 2024-12-05
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s) De Luca, Domenico

Abrégé

A healthcare data system. The system comprises a data protection entity configured to: sign at least a portion of a routing header of a data packet with a private key held by the data protection entity, the data packet including a payload and a routing header, the payload including healthcare data and the routing header indicating an intended consumer of the data packet; and transmit the data packet on towards the intended consumer. The healthcare data system further comprises one or more data receivers, each configured to: receive the data packet; and verify the signed routing header.

Classes IPC  ?

  • H04L 9/40 - Protocoles réseaux de sécurité

79.

NOVEL MONOCLONAL ANTIBODIES DIRECTED AGAINST L-THYROXINE AND DIAGNOSTIC USES THEREOF

      
Numéro d'application 18662694
Statut En instance
Date de dépôt 2024-05-13
Date de la première publication 2024-12-05
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Gerg, Michael
  • Hirzel, Klaus
  • Hojer, Caroline Dorothea
  • Josel, Hans-Peter
  • Jucknischke, Ute
  • Lehmann, Holger
  • Markina, Anastasia
  • Prencipe, Giuseppe
  • Von Proff, Leopold
  • Schraeml, Michael
  • Halldórsson, Steinar

Abrégé

The present invention provides a novel monoclonal antibody specifically binding to L-Thyroxine (T4) and compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such monoclonal antibodies, host cells expressing said antibodies, methods of producing such antibodies and diagnostic methods using such monoclonal antibodies. The monoclonal antibody of the invention comprises a heavy chain variable domain (VH) comprising V or A in position 33; Y in position 50; W in position 52; I in position 98, G, A or V in position 99; Y in position 100; and I in position 100b; and a light chain variable domain (VL) comprising amino acids H or Y in position 28; N or K in position 29; W in position 32; G or A in position 91; Y, W or F in position 92; S or T in position 93; Y or F in position 95b; N, S, T or Q in position 95c; and H in position 96, wherein the positions of the amino acids in the VH and the VL are indicated according to the Kabat numbering scheme, respectively.

Classes IPC  ?

  • C07K 16/26 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des hormones
  • G01N 33/78 - Hormones de la glande thyroïde

80.

Carry case for handheld medical meter

      
Numéro d'application 29841723
Numéro de brevet D1052269
Statut Délivré - en vigueur
Date de dépôt 2022-06-08
Date de la première publication 2024-11-26
Date d'octroi 2024-11-26
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Arnold, Peter
  • Frontzek, Carolin
  • Galbraith, Sofia Elisabeth
  • Gebhard, Roman

81.

OPTICAL SYSTEM FOR FOURIER PTYCHOGRAPHY

      
Numéro d'application 18667208
Statut En instance
Date de dépôt 2024-05-17
Date de la première publication 2024-11-21
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s) Salzmann, Wenzel

Abrégé

An optical system configured for Fourier Ptychography is disclosed, comprising at least one array of light emitters, wherein each light emitter is configured for emitting at least one illumination light beam towards a sample plane; at least one lenslet array comprising a plurality of lenses, wherein each of the lenses is dedicated to at least one of the light emitters of the array of light emitters, wherein orientation and shape of the respective lens is adapted to the dedicated light emitter, wherein the lenslet array is configured for focusing the illumination light beams in the sample plane. The array of light emitters and the lenslet array are arranged such that the sample plane is illuminated by the illumination light beams under different illumination angles.

Classes IPC  ?

  • G02B 21/00 - Microscopes
  • G02B 21/36 - Microscopes aménagés pour la photographie ou la projection

82.

METHOD FOR AUTOMATED QUALITY CHECK OF CHROMATOGRAPHIC AND/OR MASS SPECTRAL DATA

      
Numéro d'application 18689808
Statut En instance
Date de dépôt 2022-09-05
Date de la première publication 2024-11-21
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Tarasov, Kirill
  • Reichert, Andreas
  • Hummel, Manuela
  • Lang, Robert
  • Wagner, Marius

Abrégé

A computer implemented method for automated quality check of chromatographic and/or mass spectral data is disclosed. The method comprises the following steps: a) (110) providing processed chromatographic and/or mass spectral data obtained by at least one mass spectrometry device (112); b) (114) classifying quality of the chromatographic and/or mass spectral data by applying at least one trained machine learning model on the chromatographic and/or mass spectral data, wherein the trained machine learning model uses at least one regression model (116), wherein the trained machine learning model is trained on at least one training dataset comprising historical and/or semi-synthetic chromatographic and/or mass spectral data, wherein the trained machine learning model is an analyte-specific trained machine learning model.

Classes IPC  ?

83.

ANALYTICAL SYSTEM AND METHOD

      
Numéro d'application 18694492
Statut En instance
Date de dépôt 2022-09-22
Date de la première publication 2024-11-21
Propriétaire
  • Roche Diagnostics Operations, Inc. (USA)
  • Hitachi High-Tech Corporation (Japon)
Inventeur(s)
  • Lang, Robert
  • Mitra, Indranil
  • Hashimoto, Yuichiro
  • Sugawara, Yuka

Abrégé

An analytical system comprising a mass spectrometer and an ionization source. The analytical system further comprises an analytical fluidic system connectable to the ionization source for infusing samples into the mass spectrometer via the ionization source, a downstream pump fluidically connectable to the ionization source via the downstream valve, where the downstream pump is fluidically connected to a plurality of fluid containers comprising respective fluids, the fluids comprising a concentrated composition for calibrating the mass spectrometer and at least one diluent for diluting the at least one concentrated composition. The analytical system further comprises a controller configured to control the downstream pump to obtain at least one diluted composition by automatically mixing a concentrated composition with a diluent with a predetermined dilution factor, to infuse the diluted composition into the ionization source, to obtain a mass spectrum of the diluted composition and to execute a calibration of the mass spectrometer. A respective automated analytical method.

Classes IPC  ?

  • G01N 30/86 - Analyse des signaux
  • G01N 30/02 - Chromatographie sur colonne
  • G01N 30/32 - Contrôle des paramètres physiques du fluide vecteur de la pression ou de la vitesse
  • G01N 30/72 - Spectromètres de masse

84.

DOUBLE SINGLE-ION MONITORING MASS SPECTROMETRY

      
Numéro d'application EP2024063474
Numéro de publication 2024/236093
Statut Délivré - en vigueur
Date de dépôt 2024-05-16
Date de publication 2024-11-21
Propriétaire
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Ciniawsky, Susanne
  • Leinenbach, Andreas
  • Mitra, Indranil
  • Nandania, Jatin

Abrégé

The present invention relates to a method for determining an analyte in a mass spectrometry (MS) device comprising a first and a second mass filter, said method comprising (i) filtering for an analyte ion species in the first mass filter; (ii) optionally fragmenting at least a fraction of ions obtained by the filtering in step (i) in a collision cell, wherein the collision energy of said fragmenting is selected to be lower than a predetermined collision energy causing fragmentation of said analyte ion species; (iii) filtering for said analyte ion species filtered for in step (i) in the second mass filter, and (iv) detecting said analyte ion species filtered for in step (iii), thereby determining said analyte. Moreover, the present invention relates to devices, systems, and uses related to said method.

Classes IPC  ?

  • H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules

85.

NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF

      
Numéro d'application 18669957
Statut En instance
Date de dépôt 2024-05-21
Date de la première publication 2024-11-14
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Gerg, Michael
  • Heindl, Dieter
  • Hillringhaus, Lars
  • Hirzel, Klaus
  • Hojer, Caroline Dorothea
  • Huber, Florian
  • Josel, Hans-Peter
  • Meier, Thomas
  • Schraeml, Michael
  • Voss, Edgar

Abrégé

The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.

Classes IPC  ?

  • G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
  • C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs

86.

METHODS AND SYSTEMS OF SAMPLE QUALITY VERIFICATION

      
Numéro d'application 18636375
Statut En instance
Date de dépôt 2024-04-16
Date de la première publication 2024-11-07
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Glauser, Michael
  • Gutmann, Oliver
  • Janner, Gabriele Piero
  • Sarofim, Emad
  • Schweighauser, Stephan
  • Thomann, Marcel
  • Vollenweider, Urs

Abrégé

A computer-implemented method for optimising an assignment of one or more medical samples to one or more analytical tests to be conducted on those medical samples. The method comprises the steps of: obtaining an initial assignment of the one or more medical samples to the one or more analytical tests; determining a compliance status for the or each medical sample, the compliance status indicating: (i) whether a sample quality metric of the or each medical sample violates an analytical test specification of the medical sample's assigned analytical test(s) in the initial assignment and/or (ii) whether the or each medical sample is unprocessable; and performing a mitigation action if one or more compliance status indicate: (i) that the sample quality metric of a given medical sample violates the analytical test specification and/or (ii) a given medical sample is unprocessable.

Classes IPC  ?

  • G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient

87.

TRANSPORT DEVICE AND LABORATORY SAMPLE DISTRIBUTION SYSTEM

      
Numéro d'application 18649151
Statut En instance
Date de dépôt 2024-04-29
Date de la première publication 2024-11-07
Propriétaire Roche Diagnostics Operations, Inc. (Inde)
Inventeur(s)
  • Sharpe, Nathaniel
  • Nussbaum, Matthew
  • Edelmann, Matthias
  • Bates, Christopher William

Abrégé

The invention relates to a transport device for a laboratory sample distribution system, the transport device comprising a top cover having a transport surface, the transport surface being adapted to carry sample container carriers, an electromagnetic actuation assembly, the electromagnetic actuation assembly being adapted to generate a magnetic field at the transport surface for magnetic drive-interaction with a sample container carrier placed thereon, a support structure for carrying the actuation assembly, a sensor board being arranged in between the support structure and the top cover, the sensor board being adapted to detect a position of a sample container carrier placed on the transport surface with respect to the transport device, and elastic elements which are biased in between the sensor board and the support structure so that the sensor board is held flush against an inside surface of the top cover by a biasing force resulting from the biasing of the elastic elements.

Classes IPC  ?

  • B65G 54/02 - Transporteurs non mécaniques, non prévus ailleurs électrostatiques, électriques ou magnétiques
  • G01N 35/04 - Détails du transporteur

88.

ON-BOARD CONJUGATION

      
Numéro d'application 18645358
Statut En instance
Date de dépôt 2024-04-24
Date de la première publication 2024-10-31
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s) Hoogendijk, Jan-Gerrit

Abrégé

The present invention relates to a method for labeling an analyte in a sample, said method comprising (a) providing a detection agent binding to the analyte and conjugating said detection agent with an indicator agent to produce a conjugation product; (b) contacting said sample with said conjugation product of step (a); wherein said step (b) is performed directly after completion of step (a) and wherein steps (a) and (b) are performed by the same labeling device; and to labeling devices, systems, and uses related thereto.

Classes IPC  ?

  • G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
  • G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

89.

ADJUSTABLE ADAPTER AND LABORATORY SYSTEM

      
Numéro d'application 18642895
Statut En instance
Date de dépôt 2024-04-23
Date de la première publication 2024-10-31
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Gutmann, Timo
  • Meyer, Sascha

Abrégé

The invention relates to an adjustable adapter for closing a c-shaped gap in between two modules of a laboratory system, the adjustable adapter comprising a base extending along a width direction (W) of the adjustable adapter, and a pair of legs each protruding from the base in a length direction (L) of the adjustable adapter so that the base and the legs are arranged in a c-shape of the adjustable adapter, the base being adjustable to set its dimension (D, D1, D2) along the length direction (L).

Classes IPC  ?

  • B01L 9/02 - Paillasses ou tables de laboratoireLeurs garnitures

90.

A NOVEL ANTIBODY FOR DETECTION OF AMYLOID BETA 42 (AB42)

      
Numéro d'application 18745539
Statut En instance
Date de dépôt 2024-06-17
Date de la première publication 2024-10-24
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Jethwa, Alexander
  • Oelschlaegel, Tobias
  • Schindler, Corinna
  • Soukupova, Monika
  • Stoeckl, Laura
  • Zimmermann, Christina

Abrégé

The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 with advantageous features for Aβ42 detection in vitro using immunoassays. Also provided is a polynucleotide or a set of polynucleotides encoding the same and a vector comprising said polynucleotide(s). Further provided is a host cell comprising the polynucleotide(s) and a corresponding production process using this host cell. Also provided herein are uses and methods employing the monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 as provided herein.

Classes IPC  ?

  • C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
  • G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

91.

Automatic Analyzer

      
Numéro d'application 18683438
Statut En instance
Date de dépôt 2022-06-29
Date de la première publication 2024-10-24
Propriétaire
  • Hitachi High-Tech Corporation (Japon)
  • Roche Diagnostics Operation, Inc. (USA)
Inventeur(s)
  • Miyada, Yuki
  • Foester, Elisabeth
  • Steigenberger, Maximilian

Abrégé

There is provided an automatic analyzer equipped with a disk-type container placement mechanism, which enables an operator to perform additional placement of a container during analysis operation. The automatic analyzer includes a storage unit previously stored with a sample container 103 holding a sample before measurement of the sample, a dispensing mechanism 4 that sucks the sample from the sample container, an input unit that receives a command to store an emergency sample in the storage unit, the control unit 7 that controls such that, after a first operation being performed by the dispensing mechanism at a point of time when the command is received is completed, a second operation scheduled to be performed next by the dispensing mechanism is not started, and a display unit that prompts a user to store the emergency sample in the storage unit, in which the storage unit includes a first storage unit that stores an ordinary sample and a second storage unit that stores the emergency sample, and after controlling such that the second operation is not started, the control unit controls the second storage unit to move to a position where the emergency sample is inserted by a user.

Classes IPC  ?

  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
  • G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
  • G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection

92.

SYSTEMS AND METHODS FOR SECURE DATA STORAGE

      
Numéro d'application 18618670
Statut En instance
Date de dépôt 2024-03-27
Date de la première publication 2024-10-17
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Alex Namasivayam, Aishwarya
  • Britz, Jochen
  • Bucheli, Stefan
  • Cristino, Ricardo
  • Findeisen, Stanislaw
  • Kocademir, Alper
  • Roy, Sudipto Shekhar
  • Sonnenberg, Gerhard

Abrégé

A system for securely storing data, such as sensitive personal data, including an interface configured with a REST API, an authentication module, at least one target database for storing the data, and a data access module which is configured to receive requests from a client computer by means of the interface, query data from the at least one target database in response to the received request, determine whether the client computer and/or the user has permission to query, and generate a response data set to respond to the request and transmit it to the client computer, wherein at least some data of the response data set is anonymised if restricted authentication is determined.

Classes IPC  ?

  • G06F 21/62 - Protection de l’accès à des données via une plate-forme, p. ex. par clés ou règles de contrôle de l’accès

93.

METHOD AND SENSOR DEVICE FOR DETERMINING THE CONCENTRATION OF AN ANALYTE IN A SAMPLE

      
Numéro d'application 18751505
Statut En instance
Date de dépôt 2024-06-24
Date de la première publication 2024-10-17
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Bradbury, Christopher
  • Gutiérrez-Sanz, Oscar

Abrégé

A method of determining the concentration of an analyte comprising: providing a sensor device comprising: a field effect transistor having a source electrode, a drain electrode and a gate electrode, a sensing electrode electrically connected or integrated into the gate electrode, and a control device for applying operation parameters to the field effect transistor and for monitoring a signal value with the field effect transistor; selecting a set of operation parameters of the field effect transistor, the selecting comprising performing evaluation measurements with the field effect transistor using various sets of operation parameter candidates and selecting a set in accordance with optimization criterion monitored during the evaluation measurements; and detecting the concentration by applying the selected set of operation parameters to the field effect transistor and determining a signal value with the field effect transistor. A method of determining the concentration of an analyte comprising: providing a sensor device comprising: a field effect transistor having a source electrode, a drain electrode and a gate electrode, a sensing electrode electrically connected or integrated into the gate electrode, and a control device for applying operation parameters to the field effect transistor and for monitoring a signal value with the field effect transistor; selecting a set of operation parameters of the field effect transistor, the selecting comprising performing evaluation measurements with the field effect transistor using various sets of operation parameter candidates and selecting a set in accordance with optimization criterion monitored during the evaluation measurements; and detecting the concentration by applying the selected set of operation parameters to the field effect transistor and determining a signal value with the field effect transistor. Further, a sensor device for determining the concentration of an analyte in a sample.

Classes IPC  ?

  • G01N 27/414 - Transistors à effet de champ sensibles aux ions ou chimiques, c.-à-d. ISFETS ou CHEMFETS
  • G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

94.

LABORATORY APPARATUS, LABORATORY SYSTEM, AND USE

      
Numéro d'application 18750107
Statut En instance
Date de dépôt 2024-06-21
Date de la première publication 2024-10-17
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Apodaca Lujan, Leon Felipe
  • Gutmann, Timo

Abrégé

A laboratory apparatus comprising a housing, wherein the housing comprises a through-opening, wherein the through-opening is adapted for passing through it a transport device for transporting laboratory sample containers in and/or out of the housing, and a cover, wherein the cover comprises at least two ring segments, wherein the ring segments are adjustable to each other between a distant adjustment with at least one distance in between ends of the ring segments for arranging them around the passed through transport device and a near adjustment with less or no distance in between the ends of the ring segments for surrounding the passed through transport device, and wherein the cover in the near adjustment is adapted to cover a part of the through-opening left free by the passed through transport device, wherein the laboratory apparatus is a pre-analytical, analytical, and/or post-analytical laboratory apparatus, in particular a sorting module.

Classes IPC  ?

95.

MODIFIED ANTIBODY FOR SITE-SPECIFIC CONJUGATION AND ITS DIAGNOSTIC USE

      
Numéro d'application 18752484
Statut En instance
Date de dépôt 2024-06-24
Date de la première publication 2024-10-17
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Mohamed, Mohamed Yosry Hassan
  • Oelschlaegel, Tobias

Abrégé

The present invention relates to a modified antibody comprising a heavy chain and a light chain, wherein the antibody is modified to include in one or more of its immunoglobulin polypeptide chains one or more first recognition site(s) for the transglutaminase from Kutzneria albida (KalbTG) or a functionally active variant thereof. The one or more first recognition site(s) are introduced at one or more selected position(s) within an antibody's heavy chain and/or an antibody's light chain. The invention further relates to one or more nucleic acid(s) encoding an immunoglobulin polypeptide chain including the one or more recognition site(s), a site-specifically conjugated antibody comprising the modified antibody and one or more labelling domain(s) covalently attached to one or more first recognition sites, a kit for producing the conjugated antibody, a method of specifically labelling the modified antibody by way of site-specific conjugation, the use of the modified antibody for producing a specifically site-specifically conjugated antibody, a method of detecting a target in a sample and the use of the site-specifically conjugated antibody in the detection of a target and/or in the diagnosis.

Classes IPC  ?

  • C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

96.

IN VITRO CULTIVATION METHOD FOR ANTIBODY EXPRESSING CELLS

      
Numéro d'application EP2024059116
Numéro de publication 2024/208936
Statut Délivré - en vigueur
Date de dépôt 2024-04-04
Date de publication 2024-10-10
Propriétaire
  • F. HOFFMANN-LA ROCHE AG (Suisse)
  • ROCHE DIAGNOSTICS GMBH (Allemagne)
  • ROCHE DIAGNOSTICS OPERATIONS, INC. (USA)
Inventeur(s)
  • Brockhaus, Janis
  • Buchenberg, Sebastian
  • Hojer, Caroline Dorothea
  • Meier, Thomas

Abrégé

The present invention relates to an in vitro method for cultivating one or more antibody expressing cell(s). The method comprises cultivating one or more antibody expressing cell(s) obtained from peripheral blood in the presence of IL-2, IL-21 and a non-cell surface presented CD40-stimulating agent and in the absence of feeder cells. Moreover, herein provided are methods for producing antibodies comprising the step of cultivating one or more antibody expressing cell(s) according to the method of the invention, a novel CD40-stimulating agent and uses therefrom as well as a cell culture medium.

Classes IPC  ?

97.

LIGHT SOURCE FOR GENERATING ILLUMINATION LIGHT

      
Numéro d'application 18620273
Statut En instance
Date de dépôt 2024-03-28
Date de la première publication 2024-10-10
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s) Salzmann, Wenzel

Abrégé

A light source (112) for generating illumination light for illuminating at least one sample is disclosed. The light source (112) comprises at least one array of light emitters (114), wherein each of the light emitters (114) is configured for emitting at least one light beam along a light beam path, wherein the light beam has a predefined wavelength range, and at least one reflective optical grating (116) configured for overlaying the light beam paths, at least one transfer element (118); wherein the transfer element (118) is arranged between the array of light emitters (114) and the optical grating (116) such that the transfer element (118) directs the emitted light beams onto the optical grating (116) and provides the light beams reflected from the optical grating (116) and impinging on the transfer element (118) into at least one measurement channel (120), wherein the measurement channel (120) is configured for receiving at least one sample.

Classes IPC  ?

  • G01N 21/359 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant la lumière de l'infrarouge proche
  • G01N 21/33 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière ultraviolette
  • G01N 21/3577 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de liquides, p. ex. l'eau polluée

98.

COBAS TURN

      
Numéro de série 98792186
Statut En instance
Date de dépôt 2024-10-09
Propriétaire Roche Diagnostics Operations, Inc. ()
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 10 - Appareils et instruments médicaux

Produits et services

Medical diagnostic reagents, namely, chemical, biochemical and biological-based medical diagnostic reagents; diagnostic reagents for clinical medical purposes; medical diagnostic reagents for clinical medical purposes; diagnostic reagents for medical use in in-vitro diagnosis used by medical laboratories Medical apparatus, namely, clinical chemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes

99.

TRANSFER DEVICE FOR TRANSFERRING SAMPLE CONTAINERS IN A SAMPLE HANDLING SYSTEM

      
Numéro d'application 18579561
Statut En instance
Date de dépôt 2022-07-15
Date de la première publication 2024-10-03
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Narayana, Avinash Addihalli
  • Huber, Tobias

Abrégé

A transfer device (110) for transferring sample containers in a sample handling system (112) is disclosed. The transfer device (110) comprises: at least one transport device (114) comprising an array (116) of electromagnetic actuators (118), specifically electromagnetic actuators (118) comprising electromagnetic coils (120); at least one moving unit (122) comprising at least one permanent magnet (124), wherein the moving unit (122) is movable in at least one movement plane (126), specifically in at least one movement plane (126) of the moving unit (122) defined by at least two moving directions (128), through the array (116) by magnetic interaction of the permanent magnet (124) with the electromagnetic actuators (118); and at least one gripper unit (130) for positioning at least one of the sample containers, wherein the gripper unit (130) is movable in at least one gripping direction (132) essentially perpendicular to the movement plane (126), wherein the gripping unit (130) is attached to the moving unit (122). A transfer device (110) for transferring sample containers in a sample handling system (112) is disclosed. The transfer device (110) comprises: at least one transport device (114) comprising an array (116) of electromagnetic actuators (118), specifically electromagnetic actuators (118) comprising electromagnetic coils (120); at least one moving unit (122) comprising at least one permanent magnet (124), wherein the moving unit (122) is movable in at least one movement plane (126), specifically in at least one movement plane (126) of the moving unit (122) defined by at least two moving directions (128), through the array (116) by magnetic interaction of the permanent magnet (124) with the electromagnetic actuators (118); and at least one gripper unit (130) for positioning at least one of the sample containers, wherein the gripper unit (130) is movable in at least one gripping direction (132) essentially perpendicular to the movement plane (126), wherein the gripping unit (130) is attached to the moving unit (122). Further disclosed is a sample handling system (112) for handling a plurality of sample containers and a method for transferring sample containers in a sample handling system (112).

Classes IPC  ?

  • G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
  • B25J 15/02 - Têtes de préhension servocommandées

100.

METHOD FOR DETERMINING AN ANALYTE OF INTEREST BY FREQUENCY DETECTION

      
Numéro d'application 18672786
Statut En instance
Date de dépôt 2024-05-23
Date de la première publication 2024-09-19
Propriétaire Roche Diagnostics Operations, Inc. (USA)
Inventeur(s)
  • Rempt, Martin
  • Wellner, Christian

Abrégé

The present invention relates to a method for determining an analyte of interest by frequency detection and the use thereof, a modified nanopore, an analyzing system, a kit and the uses thereof.

Classes IPC  ?

  • G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
  1     2     3     ...     15        Prochaine page